QUARTERLY REPORT

Q3 2020 — Form 10-Q

Q3 2020PDF · 73 pages1.0 MB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 10-Q
________________________________________________________
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended October 2, 2020
OR
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-08089
DANAHER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 59-1995548
(State of Incorporation) (I.R.S. Employer Identification Number)
2200 Pennsylvania Avenue, N.W., Suite 800W 20037-1701
Washington, DC
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: 202-828-0850
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value DHR New York Stock Exchange
4.75% Mandatory Convertible Preferred Stock,
Series A, without par value DHR.PRA New York Stock Exchange
5.00% Mandatory Convertible Preferred Stock,
Series B, without par value DHR.PRB New York Stock Exchange
Floating Rate Senior Notes due 2022 DHR/22A New York Stock Exchange
1.700% Senior Notes due 2022 DHR/22 New York Stock Exchange
1.700% Senior Notes due 2024 DHR 24 New York Stock Exchange
2.500% Senior Notes due 2025 DHR/25 New York Stock Exchange
0.200% Senior Notes due 2026 DHR/26 New York Stock Exchange
2.100% Senior Notes due 2026 DHR 26 New York Stock Exchange
1.200% Senior Notes due 2027 DHR/27 New York Stock Exchange
0.450% Senior Notes due 2028 DHR/28 New York Stock Exchange
2.500% Senior Notes due 2030 DHR 30 New York Stock Exchange
0.750% Senior Notes due 2031 DHR/31 New York Stock Exchange
1.350% Senior Notes due 2039 DHR/39 New York Stock Exchange
1.800% Senior Notes due 2049 DHR/49 New York Stock Exchange

-- 1 of 73 --

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☒ Accelerated Filer ☐
Non-accelerated Filer ☐ Smaller Reporting Company ☐
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act) Yes ☐ No ☒
The number of shares of common stock outstanding at October 16, 2020 was 710,377,467.

-- 2 of 73 --

DANAHER CORPORATION
INDEX
FORM 10-Q
Page
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Condensed Balance Sheets 1
Consolidated Condensed Statements of Earnings 2
Consolidated Condensed Statements of Comprehensive Income 3
Consolidated Condensed Statements of Stockholders’ Equity 4
Consolidated Condensed Statements of Cash Flows 5
Notes to Consolidated Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
Item 3. Quantitative and Qualitative Disclosures About Market Risk 52
Item 4. Controls and Procedures 52
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 53
Item 1A. Risk Factors 53
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55
Item 6. Exhibits 56
Signatures 57

-- 3 of 73 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ and shares in millions, except per share amount)
(unaudited)
October 2, 2020 December 31, 2019
ASSETS
Current assets:
Cash and equivalents $ 5,687.7 $ 19,912.3
Trade accounts receivable, less allowance for doubtful accounts of $131.8 and $103.7,
respectively 3,495.7 3,191.4
Inventories:
Finished goods 1,318.6 833.5
Work in process 392.9 284.9
Raw materials 710.2 509.9
Total inventories 2,421.7 1,628.3
Prepaid expenses and other current assets 936.1 864.6
Total current assets 12,541.2 25,596.6
Property, plant and equipment, net of accumulated depreciation of $3,038.6 and $2,761.4,
respectively 3,052.3 2,302.0
Other long-term assets 2,173.3 1,720.8
Goodwill 34,269.7 22,712.5
Other intangible assets, net 20,854.2 9,749.7
Total assets $ 72,890.7 $ 62,081.6
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable and current portion of long-term debt $ 19.7 $ 212.4
Trade accounts payable 1,678.3 1,514.4
Accrued expenses and other liabilities 4,340.4 3,205.3
Total current liabilities 6,038.4 4,932.1
Other long-term liabilities 7,073.7 5,350.9
Long-term debt 21,806.1 21,516.7
Stockholders’ equity:
Preferred stock, no par value, 15.0 million shares authorized; 1.65 million shares of
4.75% Mandatory Convertible Preferred Stock, Series A, issued and outstanding as of
October 2, 2020 and December 31, 2019; 1.72 million shares of 5.00% Mandatory
Convertible Preferred Stock, Series B, issued and outstanding as of October 2, 2020
and no shares issued or outstanding as of December 31, 2019 3,267.7 1,599.6
Common stock - $0.01 par value, 2.0 billion shares authorized; 850.6 million issued
and 710.3 million outstanding as of October 2, 2020; 835.5 million issued and 695.5
million outstanding as of December 31, 2019 8.5 8.4
Additional paid-in capital 9,618.1 7,564.6
Retained earnings 26,087.8 24,166.3
Accumulated other comprehensive income (loss) (1,021.1) (3,068.3)
Total Danaher stockholders’ equity 37,961.0 30,270.6
Noncontrolling interests 11.5 11.3
Total stockholders’ equity 37,972.5 30,281.9
Total liabilities and stockholders’ equity $ 72,890.7 $ 62,081.6
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
1

-- 4 of 73 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 5,883.2 $ 4,378.0 $ 15,523.7 $ 13,042.7
Cost of sales (2,657.7) (1,936.6) (7,002.8) (5,762.6)
Gross profit 3,225.5 2,441.4 8,520.9 7,280.1
Operating costs:
Selling, general and administrative
expenses (1,795.3) (1,382.5) (4,939.0) (4,140.2)
Research and development expenses (342.6) (282.6) (952.2) (832.2)
Operating profit 1,087.6 776.3 2,629.7 2,307.7
Nonoperating income (expense):
Other (expense) income, net 6.4 4.2 4.2 14.3
Gain on sale of product lines — — 454.6 —
Interest expense (76.7) (24.0) (202.7) (64.2)
Interest income 4.2 30.1 67.7 72.0
Earnings from continuing operations before
income taxes 1,021.5 786.6 2,953.5 2,329.8
Income taxes (138.0) (155.9) (547.6) (690.4)
Net earnings from continuing operations 883.5 630.7 2,405.9 1,639.4
Earnings from discontinued operations, net
of income taxes — 37.3 — 93.7
Net earnings 883.5 668.0 2,405.9 1,733.1
Mandatory convertible preferred stock
dividends (41.1) (19.6) (95.3) (48.8)
Net earnings attributable to common
stockholders $ 842.4 $ 648.4 $ 2,310.6 $ 1,684.3
Net earnings per common share from
continuing operations:
Basic $ 1.18 $ 0.85 $ 3.28 (a) $ 2.23
Diluted $ 1.16 $ 0.84 $ 3.22 $ 2.20
Net earnings per common share from
discontinued operations:
Basic $ — $ 0.05 $ — $ 0.13
Diluted $ — $ 0.05 $ — $ 0.13
Net earnings per common share:
Basic $ 1.18 $ 0.90 $ 3.28 (a) $ 2.36
Diluted $ 1.16 $ 0.89 $ 3.22 $ 2.32 (b)
Average common stock and common
equivalent shares outstanding:
Basic 710.9 718.8 704.4 714.7
Diluted 724.3 729.3 716.8 725.2
(a) Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amounts due to
rounding.
(b) Net earnings per common share amount does not add due to rounding.
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
2

-- 5 of 73 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
($ in millions)
(unaudited)
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Net earnings $ 883.5 $ 668.0 $ 2,405.9 $ 1,733.1
Other comprehensive income (loss), net of income
taxes:
Foreign currency translation adjustments 922.8 (235.8) 1,845.6 (293.1)
Pension and postretirement plan benefit
adjustments 8.9 5.8 25.0 15.8
Unrealized gain on available-for-sale securities
adjustments — 0.5 1.0 1.4
Cash flow hedge adjustments (89.7) (41.8) 175.6 (48.6)
Total other comprehensive income (loss), net of
income taxes 842.0 (271.3) 2,047.2 (324.5)
Less: other comprehensive loss attributable to
noncontrolling interest — 1.2 — 1.2
Comprehensive income attributable to Danaher $ 1,725.5 $ 397.9 $ 4,453.1 $ 1,409.8
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
3

-- 6 of 73 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
($ in millions)
(unaudited)
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Preferred stock:
Balance, beginning of period $ 3,267.7 $ 1,599.6 $ 1,599.6 $ —
Issuance of Mandatory Convertible
Preferred Stock — — 1,668.1 1,599.6
Balance, end of period $ 3,267.7 $ 1,599.6 $ 3,267.7 $ 1,599.6
Common stock:
Balance, beginning of period $ 8.5 $ 8.3 $ 8.4 $ 8.2
Issuance of common stock — — 0.1 0.1
Balance, end of period $ 8.5 $ 8.3 $ 8.5 $ 8.3
Additional paid-in capital:
Balance, beginning of period $ 9,475.1 $ 7,482.6 $ 7,564.6 $ 5,834.3
Common stock-based award activity 103.6 77.6 274.9 253.2
Common stock issued in connection with
LYONs’ conversions, including tax benefit
of $39.2, $0.4, $42.2 and $8.5, respectively 39.4 1.3 50.2 30.9
Issuance of common stock — — 1,728.4 1,443.1
Sale of Envista Holdings Corporation
Common Stock — (60.0) — (60.0)
Balance, end of period $ 9,618.1 $ 7,501.5 $ 9,618.1 $ 7,501.5
Retained earnings:
Balance, beginning of period $ 25,373.5 $ 25,955.0 $ 24,166.3 $ 25,163.0
Adoption of accounting standards — — (7.6) —
Net earnings 883.5 668.0 2,405.9 1,733.1
Dividends declared for common stock (128.1) (122.2) (381.5) (366.1)
Mandatory Convertible Preferred Stock
cumulative dividends (41.1) (19.6) (95.3) (48.8)
Balance, end of period $ 26,087.8 $ 26,481.2 $ 26,087.8 $ 26,481.2
Accumulated other comprehensive income (loss):
Balance, beginning of period $ (1,863.1) $ (2,844.3) $ (3,068.3) $ (2,791.1)
Sale of Envista Holdings Corporation
Common Stock — 26.1 — 26.1
Other comprehensive income (loss) 842.0 (270.1) 2,047.2 (323.3)
Balance, end of period $ (1,021.1) $ (3,088.3) $ (1,021.1) $ (3,088.3)
Noncontrolling interests:
Balance, beginning of period $ 11.2 $ 12.0 $ 11.3 $ 12.3
Sale of Envista Holdings Corporation
Common Stock — 676.7 — 676.7
Change in noncontrolling interests 0.3 4.6 0.2 4.3
Balance, end of period $ 11.5 $ 693.3 $ 11.5 $ 693.3
Total stockholders’ equity, end of period $ 37,972.5 $ 33,195.6 $ 37,972.5 $ 33,195.6
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
4

-- 7 of 73 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)
Nine-Month Period Ended
October 2, 2020 September 27, 2019
Cash flows from operating activities:
Net earnings $ 2,405.9 $ 1,733.1
Less: earnings from discontinued operations, net of income taxes — 93.7
Net earnings from continuing operations 2,405.9 1,639.4
Noncash items:
Depreciation 464.8 420.5
Amortization of intangible assets 801.6 469.3
Amortization of inventory step-up 417.2 —
Stock-based compensation expense 137.1 117.5
Pretax gain on sale of product lines (454.6) —
Change in trade accounts receivable, net 211.4 (22.3)
Change in inventories (243.7) (164.9)
Change in trade accounts payable (107.0) (48.6)
Change in prepaid expenses and other assets 45.9 235.1
Change in accrued expenses and other liabilities 315.1 15.7
Total operating cash provided by continuing operations 3,993.7 2,661.7
Total operating cash (used in) provided by discontinued operations (7.0) 178.7
Net operating cash provided by operating activities 3,986.7 2,840.4
Cash flows from investing activities:
Cash paid for acquisitions (20,818.5) (331.1)
Payments for additions to property, plant and equipment (475.2) (456.5)
Proceeds from sales of property, plant and equipment 1.4 12.5
Payments for purchases of investments (214.9) (163.4)
Proceeds from sale of product lines 825.9 —
All other investing activities 23.6 29.1
Total investing cash used in continuing operations (20,657.7) (909.4)
Total investing cash used in discontinued operations — (62.6)
Net operating cash used in investing activities (20,657.7) (972.0)
Cash flows from financing activities:
Proceeds from the issuance of common stock in connection with stock-based compensation 125.2 115.0
Proceeds from the sale of common stock, net of issuance costs 1,728.5 1,443.2
Proceeds from the sale of preferred stock, net of issuance costs 1,668.1 1,599.6
Proceeds from the sale of Envista Holdings Corporation common stock, net of issuance costs — 643.4
Payment of dividends (445.4) (385.0)
Net (repayments of) proceeds from borrowings (maturities of 90 days or less) (3,339.3) 744.1
Net proceeds from borrowings (maturities longer than 90 days) 7,691.3 8,137.1
Net repayments of borrowings (maturities longer than 90 days) (5,000.0) (680.9)
All other financing activities (2.7) (6.0)
Net operating cash provided by financing activities 2,425.7 11,610.5
Effect of exchange rate changes on cash and equivalents 20.7 (14.6)
Net change in cash and equivalents (14,224.6) 13,464.3
Beginning balance of cash and equivalents 19,912.3 787.8
Ending balance of cash and equivalents $ 5,687.7 $ 14,252.1
Supplemental disclosures:
Cash interest payments $ 234.8 $ 112.9
Cash income tax payments 644.1 494.8
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
5

-- 8 of 73 --

DANAHER CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(unaudited)
NOTE 1. GENERAL
The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or
the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In
this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its
consolidated subsidiaries, (unless otherwise indicated or the context otherwise requires) or the consolidated subsidiaries of
Danaher Corporation, as the context requires. Certain information and footnote disclosures normally included in financial
statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been
condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate
to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should
be read in conjunction with the financial statements as of and for the year ended December 31, 2019 and the Notes thereto
included in the Company’s 2019 Annual Report on Form 10-K filed on February 21, 2020 (the “2019 Annual Report”).
In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal
recurring accruals) necessary to present fairly the financial position of the Company as of October 2, 2020 and December 31,
2019, its results of operations for the three and nine-month periods ended October 2, 2020 and September 27, 2019 and its cash
flows for each of the nine-month periods then ended.
Accounting Standards Recently Adopted—In August 2018, the Financial Accounting Standards Board (“FASB”) issued
Accounting Standards Update (“ASU”) No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosures on
fair value measurements by removing the requirement to disclose the amount and reasons for transfers between Level 1 and
Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements
for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other
comprehensive income (loss). The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with
early adoption permitted. On January 1, 2020, the Company adopted the ASU and the ASU did not have a significant impact
on the Company’s Consolidated Condensed Financial Statements. Refer to Note 6 for the Company’s fair value measurement
disclosures.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach
based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including
trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities
for fiscal years beginning after December 15, 2019, with early adoption permitted. In November 2018, the FASB issued ASU
No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which provided additional
implementation guidance on the previously issued ASU. On January 1, 2020, the Company adopted the ASU using the
modified retrospective transition method. The Company recorded a net decrease to beginning retained earnings of $8 million as
of January 1, 2020 due to the cumulative impact of adopting Topic 326. The impact to retained earnings was primarily the
result of an increase in the Company’s allowance for doubtful accounts as a result of Topic 326’s requirement to use a forward-
looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial
instruments, including trade receivables. As a result of the adoption of the ASU, the Company’s allowance for doubtful
accounts as of October 2, 2020 reflects the Company’s best estimate of the expected future losses for its accounts receivables
based on the current economic conditions; however, as a result of the uncertainty caused by the coronavirus (COVID-19)
pandemic and other factors, these estimates may change and future actual losses may differ from the Company’s estimates. The
Company will continue to monitor economic conditions and will revise the estimates of the expected future losses for accounts
receivable as necessary.
Table of Contents
6

-- 9 of 73 --

Accounting Standards Not Yet Adopted—In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—
Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715, Compensation—Retirement
Benefits, to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans.
The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted.
Management has not yet completed its assessment of the impact of the new standard on the Company’s financial statements.
In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s
Own Equity. The ASU includes amendments to the guidance on convertible instruments and the derivative scope exception for
contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial
conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, the
ASU will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible
instruments. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those
fiscal years. Management has not yet completed its assessment of the impact of the new standard on the Company’s financial
statements.
Operating Leases—As of October 2, 2020 and December 31, 2019, operating lease right-of-use assets where the Company was
the lessee were $906 million and $764 million, respectively, and are included within other long-term assets in the
accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were $935 million and $797
million as of October 2, 2020 and December 31, 2019, respectively, and are included in accrued expenses and other liabilities
and other long-term liabilities.
Table of Contents
7

-- 10 of 73 --

Accumulated Other Comprehensive Income (Loss)—Accumulated other comprehensive income (loss) refers to certain gains
and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings as these
amounts are initially recorded as an adjustment to stockholders’ equity. The changes in accumulated other comprehensive
income (loss) by component are summarized below ($ in millions). Foreign currency translation adjustments generally relate to
indefinite investments in non-U.S. subsidiaries, as well as the impact from the Company’s hedges of its net investment in
foreign operations, including the Company’s cross-currency swap derivatives, net of any income tax impacts.
Foreign
Currency
Translation
Adjustments
Pension &
Postretirement
Plan Benefit
Adjustments
Unrealized
Gain (Loss) on
Available-For-
Sale Securities
Adjustments
Cash Flow
Hedge
Adjustments Total
For the Three-Month Period Ended October 2, 2020:
Balance, July 3, 2020 $ (1,250.5) $ (765.4) $ 0.3 $ 152.5 $ (1,863.1)
Other comprehensive income (loss) before
reclassifications:
Increase (decrease) 908.9 — — (304.9) 604.0
Income tax impact 13.9 — — 47.8 61.7
Other comprehensive income (loss) before
reclassifications, net of income taxes 922.8 — — (257.1) 665.7
Amounts reclassified from accumulated
other comprehensive income (loss):
Increase — 11.6 (a) — 167.5 (b) 179.1
Income tax impact — (2.7) — (0.1) (2.8)
Amounts reclassified from accumulated
other comprehensive income (loss), net of
income taxes — 8.9 — 167.4 176.3
Net current period other comprehensive
income (loss), net of income taxes 922.8 8.9 — (89.7) 842.0
Balance, October 2, 2020 $ (327.7) $ (756.5) $ 0.3 $ 62.8 $ (1,021.1)
For the Three-Month Period Ended September 27, 2019:
Balance, June 28, 2019 $ (2,155.4) $ (681.1) $ (1.0) $ (6.8) $ (2,844.3)
Other comprehensive income (loss) before
reclassifications:
(Decrease) increase (226.8) — 0.6 (55.1) (281.3)
Income tax impact (9.0) — (0.1) 13.3 4.2
Other comprehensive income (loss) before
reclassifications, net of income taxes (235.8) — 0.5 (41.8) (277.1)
Amounts reclassified from accumulated
other comprehensive income (loss):
Increase — 7.5 (a) — — 7.5
Income tax impact — (1.7) — — (1.7)
Amounts reclassified from accumulated
other comprehensive income (loss), net of
income taxes — 5.8 — — 5.8
Net current period other comprehensive
income (loss), net of income taxes (235.8) 5.8 0.5 (41.8) (271.3)
(c)
Balance, September 27, 2019 $ (2,391.2) $ (675.3) $ (0.5) $ (48.6) (3,115.6)
Less: accumulated other comprehensive income attributable to noncontrolling interest (27.3)
Accumulated other comprehensive income attributable to controlling interest $ (3,088.3)
(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to
Notes 9 and 11 for additional details.
(b) Reflects reclassification to earnings related to hedges of certain long-term debt (refer to Note 8 for additional details).
(c) Accumulated other comprehensive income (loss) for the three-month period ended September 27, 2019 consists of $270.1 million of
accumulated other comprehensive loss attributable to controlling interest and $1.2 million of accumulated other comprehensive loss
attributable to noncontrolling interest.
Table of Contents
8

-- 11 of 73 --

Foreign
Currency
Translation
Adjustments
Pension &
Postretirement
Plan Benefit
Adjustments
Unrealized
Gain (Loss) on
Available-For-
Sale Securities
Adjustments
Cash Flow
Hedge
Adjustments Total
For the Nine-Month Period Ended October 2, 2020:
Balance, December 31, 2019 $ (2,173.3) $ (781.5) $ (0.7) $ (112.8) $ (3,068.3)
Other comprehensive income (loss) before
reclassifications:
Increase (decrease) 1,848.0 — 1.2 (8.4) 1,840.8
Income tax impact (2.4) — (0.2) 3.3 0.7
Other comprehensive income (loss) before
reclassifications, net of income taxes 1,845.6 — 1.0 (5.1) 1,841.5
Amounts reclassified from accumulated
other comprehensive income (loss):
Increase — 32.8 (a) — 184.5 (b) 217.3
Income tax impact — (7.8) — (3.8) (11.6)
Amounts reclassified from accumulated
other comprehensive income (loss), net of
income taxes — 25.0 — 180.7 205.7
Net current period other comprehensive
income (loss), net of income taxes 1,845.6 25.0 1.0 175.6 2,047.2
Balance, October 2, 2020 $ (327.7) $ (756.5) $ 0.3 $ 62.8 $ (1,021.1)
For the Nine-Month Period Ended September 27, 2019:
Balance, December 31, 2018 $ (2,098.1) $ (691.1) $ (1.9) $ — $ (2,791.1)
Other comprehensive income (loss) before
reclassifications:
(Decrease) increase (286.0) — 1.8 (64.0) (348.2)
Income tax impact (7.1) — (0.4) 15.4 7.9
Other comprehensive income (loss) before
reclassifications, net of income taxes (293.1) — 1.4 (48.6) (340.3)
Amounts reclassified from accumulated
other comprehensive income (loss):
Increase — 20.7 (a) — — 20.7
Income tax impact — (4.9) — — (4.9)
Amounts reclassified from accumulated
other comprehensive income (loss), net of
income taxes — 15.8 — — 15.8
Net current period other comprehensive
income (loss), net of income taxes (293.1) 15.8 1.4 (48.6) (324.5)
(c)
Balance, September 27, 2019 $ (2,391.2) $ (675.3) $ (0.5) $ (48.6) (3,115.6)
Less: accumulated other comprehensive income attributable to noncontrolling interest (27.3)
Accumulated other comprehensive income attributable to controlling interest $ (3,088.3)
(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to
Notes 9 and 11 for additional details.
(b) Reflects reclassification to earnings related to hedges of certain long-term debt (refer to Note 8 for additional details).
(c) Accumulated other comprehensive income (loss) for the nine-month period ended September 27, 2019 consists of $323.3 million of
accumulated other comprehensive loss attributable to controlling interest and $1.2 million of accumulated other comprehensive loss
attributable to noncontrolling interest.
Table of Contents
9

-- 12 of 73 --

NOTE 2. REVENUE
The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and
nine-month periods ended October 2, 2020 and September 27, 2019 ($ in millions). Sales taxes and other usage-based taxes
collected from customers are excluded from revenue.
Life Sciences Diagnostics
Environmental
& Applied
Solutions Total
For the Three-Month Period Ended October 2, 2020:
Geographical region:
North America $ 1,100.6 $ 797.8 $ 481.0 $ 2,379.4
Western Europe 779.7 349.2 245.1 1,374.0
Other developed markets 193.4 103.6 29.2 326.2
High-growth markets (a) 848.8 638.5 316.3 1,803.6
Total $ 2,922.5 $ 1,889.1 $ 1,071.6 $ 5,883.2
Revenue type:
Recurring $ 2,075.5 $ 1,541.6 $ 609.9 $ 4,227.0
Nonrecurring 847.0 347.5 461.7 1,656.2
Total $ 2,922.5 $ 1,889.1 $ 1,071.6 $ 5,883.2
For the Three-Month Period Ended September 27,
2019:
Geographical region:
North America $ 637.2 $ 602.9 $ 465.5 $ 1,705.6
Western Europe 444.1 257.9 252.8 954.8
Other developed markets 149.2 108.4 32.5 290.1
High-growth markets (a) 465.1 632.7 329.7 1,427.5
Total $ 1,695.6 $ 1,601.9 $ 1,080.5 $ 4,378.0
Revenue type:
Recurring $ 1,084.3 $ 1,343.2 $ 595.2 $ 3,022.7
Nonrecurring 611.3 258.7 485.3 1,355.3
Total $ 1,695.6 $ 1,601.9 $ 1,080.5 $ 4,378.0
Table of Contents
10

-- 13 of 73 --

Life Sciences Diagnostics
Environmental
& Applied
Solutions Total
For the Nine-Month Period Ended October 2, 2020:
Geographical region:
North America $ 2,721.1 $ 2,243.5 $ 1,430.1 $ 6,394.7
Western Europe 1,962.9 974.3 720.4 3,657.6
Other developed markets 524.4 297.9 88.4 910.7
High-growth markets (a) 2,006.9 1,660.6 893.2 4,560.7
Total $ 7,215.3 $ 5,176.3 $ 3,132.1 $ 15,523.7
Revenue type:
Recurring $ 5,135.0 $ 4,305.0 $ 1,809.3 $ 11,249.3
Nonrecurring 2,080.3 871.3 1,322.8 4,274.4
Total $ 7,215.3 $ 5,176.3 $ 3,132.1 $ 15,523.7
For the Nine-Month Period Ended September 27, 2019:
Geographical region:
North America $ 1,878.1 $ 1,836.3 $ 1,403.0 $ 5,117.4
Western Europe 1,363.7 828.5 774.1 2,966.3
Other developed markets 436.1 295.6 92.7 824.4
High-growth markets (a) 1,357.2 1,796.6 980.8 4,134.6
Total $ 5,035.1 $ 4,757.0 $ 3,250.6 $ 13,042.7
Revenue type:
Recurring $ 3,264.4 $ 4,047.9 $ 1,770.2 $ 9,082.5
Nonrecurring 1,770.7 709.1 1,480.4 3,960.2
Total $ 5,035.1 $ 4,757.0 $ 3,250.6 $ 13,042.7
(a) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in
gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the
exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets that are not high-growth markets.
The Company sells equipment to customers as well as consumables, software licenses and services, some of which customers
purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the
use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s
operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation
and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s
consumables are used on a standalone basis, such as water treatment solutions. The Company separates its goods and services
between those sold on a recurring basis and those sold on a nonrecurring basis. Recurring revenue includes revenue from
consumables, services, software licenses recognized over time, software-as-a-service licenses, sales-and-usage based royalties
and operating-type leases (“OTLs”). Nonrecurring revenue includes sales from equipment, software licenses recognized at a
point in time and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month
periods ended October 2, 2020 and September 27, 2019, lease revenue was $112 million and $108 million, respectively. For
the nine-month periods ended October 2, 2020 and September 27, 2019, lease revenue was $332 million and $320 million,
respectively.
Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate
transaction price allocated to performance obligations with an original contract term greater than one year which are fully or
partially unsatisfied at the end of the period. As of October 2, 2020, the aggregate amount of the transaction price allocated to
remaining performance obligations was approximately $2.8 billion. The Company expects to recognize revenue on
approximately 51% of the remaining performance obligations over the next 12 months, 22% over the subsequent 12 months,
and the remainder recognized thereafter.
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables
(“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”)
Table of Contents
11

-- 14 of 73 --

on the Consolidated Condensed Balance Sheets. Most of the Company’s long-term contracts are billed as work progresses in
accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often
this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally
classified as other current assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of October 2,
2020 and December 31, 2019 was $67 million and $77 million, respectively.
The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract
liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Condensed Balance Sheets
based on the timing of when the Company expects to recognize revenue. As of October 2, 2020 and December 31, 2019,
contract liabilities were approximately $1.3 billion and $806 million, respectively, and are included within accrued expenses
and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase
in the contract liability balance during the nine-month period ended October 2, 2020 was primarily a result of the Cytiva
Acquisition (as defined below) and cash payments received in advance of satisfying performance obligations, partially offset
by revenue recognized during the year that was included in the opening contract liability balance. Revenue recognized during
the nine-month periods ended October 2, 2020 and September 27, 2019 that was included in the contract liability balance on
December 31, 2019 and December 31, 2018 was $537 million and $497 million, respectively. Contract assets and liabilities are
reported on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis.
NOTE 3. ACQUISITIONS
For a description of the Company’s acquisition activity for the year ended December 31, 2019, reference is made to the
financial statements as of and for the year ended December 31, 2019 and Note 3 thereto included in the Company’s 2019
Annual Report.
The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or
expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions
that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial
statements. This goodwill arises because the purchase prices for these businesses reflect a number of factors including the
future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which
similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company
acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be
encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable
businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations.
The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair
value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through
other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities,
including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to
refine the estimates of fair value and more accurately allocate the purchase price. Only facts and circumstances that existed as
of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-
acquisition contingencies associated with its 2020 acquisitions (including the acquisition of Cytiva, as described below) and is
also in the process of obtaining valuations of certain acquisition-related assets and liabilities in connection with these
acquisitions. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the
measurement period, as required.
On March 31, 2020, the Company acquired the Biopharma business of General Electric Company’s (“GE”) Life Sciences
division, now known as Cytiva, for a cash purchase price of approximately $20.7 billion (net of approximately $0.1 billion of
acquired cash) and the assumption of approximately $0.4 billion of pension liabilities (the “Cytiva Acquisition”). Cytiva is a
leading provider of instruments, consumables and software that support the research, discovery, process development and
manufacturing workflows of biopharmaceutical drugs. Cytiva is included in the Company’s Life Sciences segment results
beginning in the second quarter of 2020. The acquisition has provided and is expected to provide additional sales and earnings
growth opportunities for the Company’s Life Sciences segment by expanding the business’ geographic and product line
diversity, including new product and service offerings that complement the Company’s current biologics workflow solutions.
As a condition to obtaining certain regulatory approvals for the closing of the transaction, the Company was required to divest
certain of its existing product lines in the Life Sciences segment that in the aggregate generated revenues of approximately $170
million in 2019. On April 30, 2020, the Company completed the sale of these product lines for a cash purchase price, net of
cash transferred and transaction costs, of $826 million and recognized a pretax gain on sale of $455 million ($305 million after-
tax or $0.42 per diluted common share) in the second quarter of 2020. The divestiture of these product lines did not represent a
strategic shift with a major effect on the Company’s operations and financial results and therefore will not be reported as a
discontinued operation.
Table of Contents
12

-- 15 of 73 --

The Company financed the Cytiva Acquisition with approximately $3.0 billion of proceeds from the March 1, 2019
underwritten public offerings of its Common Stock and Series A Mandatory Convertible Preferred Stock (“MCPS Series A”),
approximately $10.8 billion of proceeds from the 2019 issuance of euro-denominated and U.S. dollar-denominated long-term
debt, and approximately $6.9 billion from the aggregate of proceeds from commercial paper borrowings, borrowings under the
Company’s Five-Year Facility (as defined below) and cash on hand. The Company preliminarily recorded approximately $10.2
billion of goodwill related to the Cytiva Acquisition.
In addition to the Cytiva Acquisition, during the nine-month period ended October 2, 2020, the Company acquired one other
business for total consideration of $104 million in cash, net of cash acquired. The business acquired complements an existing
unit of the Environmental & Applied Solutions segment. The Company preliminarily recorded an aggregate of $95 million of
goodwill related to this acquisition.
The aggregate annual sales of the two businesses acquired in 2020 at the time of their acquisition, in each case based on the
companies’ revenues for its last completed fiscal year prior to the acquisition, were approximately $3.3 billion. The following
summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the nine-month
period ended October 2, 2020 ($ in millions):
Cytiva Other Total
Trade accounts receivable $ 481.7 $ 1.4 $ 483.1
Inventories 939.2 — 939.2
Property, plant and equipment 688.8 — 688.8
Goodwill 10,206.7 94.7 10,301.4
Other intangible assets, primarily technology, customer relationships and
trade names 10,655.5 16.4 10,671.9
Trade accounts payable (248.8) (0.4) (249.2)
Pension liabilities (422.8) — (422.8)
Deferred tax liabilities (1,196.5) — (1,196.5)
Other assets and liabilities, net (389.1) (8.3) (397.4)
Net cash consideration $ 20,714.7 $ 103.8 $ 20,818.5
Pro Forma Financial Information
The unaudited pro forma information for the periods set forth below gives effect to the 2020 and 2019 acquisitions as if they
had occurred as of January 1, 2019. The pro forma information is presented for informational purposes only and is not
necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been
consummated as of that time ($ in millions, except per share amounts):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 5,895.2 $ 5,113.7 $ 16,343.9 $ 15,247.8
Net earnings from continuing operations 1,064.0 719.7 2,574.1 1,545.0
Diluted net earnings per common share from
continuing operations (a) 1.41 0.96 3.46 2.04
(a) Diluted net earnings per common share from continuing operations is calculated by adding the interest on the Company’s LYONs to net
earnings from continuing operations and deducting the MCPS dividends from net earnings from continuing operations.
The 2019 unaudited pro forma sales and net earnings set forth above were adjusted to include the pretax impact of $43 million
and $480 million for the three and nine-month periods ended September 27, 2019, respectively, of non-recurring acquisition
date fair value adjustments to inventory and deferred revenue related to the Cytiva Acquisition. The 2020 unaudited pro forma
sales and net earnings from continuing operations were adjusted to exclude the impact of these items.
In addition, acquisition-related transaction costs of $30 million for the three-month period ended September 27, 2019 and $59
million and $63 million for the nine-month periods ended October 2, 2020 and September 27, 2019, respectively, associated
with the Cytiva Acquisition were excluded from pro forma net earnings from continuing operations. The pretax gain of $455
million ($305 million after-tax or $0.42 per diluted common share) for the nine-month period ended October 2, 2020 related to
the divestiture of certain product lines that was required as a condition to obtaining certain regulatory approvals for the closing
of the Cytiva Acquisition was also excluded from the 2020 pro forma net earnings from continuing operations.
Table of Contents
13

-- 16 of 73 --

NOTE 4. DISCONTINUED OPERATIONS
On December 18, 2019, Danaher completed the separation (the “Separation”) of Envista Holdings Corporation (“Envista”). For
additional details on the Separation, reference is made to the financial statements as of and for the year ended December 31,
2019 and Note 4 thereto included in the Company’s 2019 Annual Report. The accounting requirements for reporting the
Separation of Envista as a discontinued operation were met when the Separation was completed. Accordingly, the
accompanying Consolidated Condensed Financial Statements for all periods presented reflect this business as a discontinued
operation.
In connection with the Separation, Danaher and Envista entered into various agreements to effect the disposition and provide a
framework for their relationship after the Separation, including a separation agreement, transition services agreement, employee
matters agreement, tax matters agreement, intellectual property matters agreement and Danaher Business System license
agreement. These agreements provide for the allocation between Danaher and Envista of assets, employees, liabilities and
obligations (including investments, property and employee benefits and tax related assets and liabilities) attributable to periods
prior to, at and after Envista’s separation from Danaher and govern certain relationships between Danaher and Envista after the
Separation. In addition, Danaher is also party to various commercial agreements with Envista entities. The amounts paid and
received by Danaher for transition services provided under the above agreements as well as sales and purchases to and from
Envista were not material to the Company’s results of operations for the three and nine-month periods ended October 2, 2020.
The key components of income from discontinued operations for the three and nine-month periods ended September 27, 2019
were as follows ($ in millions):
Three-Month
Period Ended Nine-Month
Period Ended
Sales $ 659.3 $ 2,031.1
Cost of sales (292.3) (907.4)
Selling, general and administrative expenses (272.2) (869.7)
Research and development expenses (36.3) (119.3)
Other income 0.2 1.6
Interest expense (2.3) (6.0)
Earnings from discontinued operations before income taxes 56.4 130.3
Income taxes (13.2) (30.7)
Net earnings, net of income taxes 43.2 99.6
Net earnings attributable to noncontrolling interest (5.9) (5.9)
Earnings from discontinued operations, net of income taxes $ 37.3 $ 93.7
NOTE 5. GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2019 $ 22,712.5
Attributable to 2020 acquisitions 10,301.4
Attributable to 2020 divestitures (180.5)
Adjustments due to finalization of purchase price allocations (3.0)
Foreign currency translation and other 1,439.3
Balance, October 2, 2020 $ 34,269.7
Table of Contents
14

-- 17 of 73 --

The carrying value of goodwill by segment is summarized as follows ($ in millions):
October 2, 2020 December 31, 2019
Life Sciences $ 24,866.5 $ 13,471.8
Diagnostics 6,951.6 6,901.2
Environmental & Applied Solutions 2,451.6 2,339.5
Total $ 34,269.7 $ 22,712.5
The increase in the goodwill balance of the Life Sciences segment in the nine-month period ended October 2, 2020 is a result of
the Cytiva Acquisition. Measurement period adjustments since acquisition decreased the goodwill recognized for the Cytiva
Acquisition by approximately $1.3 billion, as the initial allocation of the purchase price was adjusted to allocate additional
purchase price to technology, customer relationships and trade names partially offset by related deferred tax liabilities. Refer to
Note 3 for more detail. The Company has not identified any “triggering” events which indicate an impairment of goodwill in
2020.
Finite-lived intangible assets are amortized over their legal or estimated useful life. The following summarizes the gross
carrying value and accumulated amortization for each major category of intangible assets ($ in millions):
October 2, 2020 December 31, 2019
Gross Carrying
Amount Accumulated
Amortization Gross Carrying
Amount Accumulated
Amortization
Finite-lived intangibles:
Patents and technology $ 11,944.3 $ (1,329.4) $ 2,712.7 $ (934.1)
Customer relationships, trade names and other
intangibles 8,942.3 (3,013.3) 6,367.4 (2,612.3)
Total finite-lived intangibles 20,886.6 (4,342.7) 9,080.1 (3,546.4)
Indefinite-lived intangibles:
Trademarks and trade names 4,310.3 — 4,216.0 —
Total intangibles $ 25,196.9 $ (4,342.7) $ 13,296.1 $ (3,546.4)
During the nine-month period ended October 2, 2020, the Company acquired finite-lived intangible assets, consisting primarily
of developed technology, customer relationships and trade names, with a weighted average life of 17 years primarily as a result
of the Cytiva Acquisition. Refer to Note 3 for additional information on the intangible assets acquired.
The Company identified impairment triggers during the first and third quarters of 2020 which resulted in the impairment of
certain long-lived assets, including trade names and other intangible assets. The Company recorded impairment charges
totaling $14 million and $22 million in the three and nine-month periods ended October 2, 2020, respectively, related to these
long-lived assets.
NOTE 6. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the
Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the
valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes
the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets
or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or
similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates,
yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through
correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s
classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement
in its entirety.
Table of Contents
15

-- 18 of 73 --

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):
Balance,
October 2, 2020
Quoted Prices in
Active Market
(Level 1)
Significant Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs (Level 3)
Assets:
Available-for-sale debt securities $ 29.6 $ — $ 29.6 $ —
Investment in equity securities 235.2 16.0 — —
Cross-currency swap derivative contracts 35.9 — 35.9 —
Liabilities:
Cross-currency swap derivative contracts 120.2 — 120.2 —
Deferred compensation plans 98.8 — 98.8 —
Balance,
December 31,
2019
Quoted Prices in
Active Market
(Level 1)
Significant Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs (Level 3)
Assets:
Available-for-sale debt securities $ 33.7 $ — $ 33.7 $ —
Investment in equity securities 110.8 — — —
Cross-currency swap derivative contracts 25.7 — 25.7 —
Liabilities:
Cross-currency swap derivative contracts 111.7 — 111.7 —
Deferred compensation plans 70.4 — 70.4 —
Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed
Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the
underlying terms of the security and comparison to similar securities traded on an active market. As of October 2, 2020,
available-for-sale debt securities primarily include U.S. Treasury Notes and corporate debt securities, which are valued based
on instruments with similar terms traded on an active market.
The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments in
non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as they are
measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates the fair value of
the investments in equity securities based on the measurement alternative and adjusts for impairments and observable price
changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The
Company’s investments in these equity securities are not classified in the fair value hierarchy due to the use of these
measurement methods. Additionally, the Company is a limited partner in a partnership that invests in early-stage companies.
While the partnership records these investments at fair value, the Company’s investment in the partnership is accounted for
under the equity method of accounting and is not subject to fair value measurement disclosures. During the three and nine-
month periods ended October 2, 2020, the Company recorded unrealized gains of $3 million and unrealized losses of $10
million, respectively, related to changes in the fair value of these investments which is reflected in other (expense) income, net
in the Company’s Consolidated Condensed Statements of Earnings. No significant realized or unrealized gains or losses were
recorded in the three and nine-month periods ended September 27, 2019 with respect to these investments.
The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in foreign operations
against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss
franc. The Company also uses cross-currency swap derivative contracts to hedge the exchange rate exposure from long-term
debt issuances in a foreign currency other than the functional currency of the borrower. The cross-currency swap derivative
contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant
interest rates and foreign currency current exchange rates and forward curves as inputs. Refer to Note 8 for additional
information.
The Company has established nonqualified contribution and deferred compensation programs that permit the Company to make
tax-deferred contributions to officers and certain other employees, and also permit directors, officers and certain other
employees to voluntarily defer taxation on a portion of their compensation. All amounts contributed or deferred under such
plans are unfunded, unsecured obligations of the Company and are presented as a component of the Company’s compensation
Table of Contents
16

-- 19 of 73 --

and benefits accrual included in other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Non-
director participants may choose among alternative earning rates for the amounts they defer, which are primarily based on
investment options within the Company’s 401(k) program. Changes in the deferred compensation liability under these
programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable
earnings rates. Amounts deferred by directors and amounts unilaterally contributed to participant accounts by the Company are
deemed invested in the Company’s common stock and future distributions of such contributions (as well as future distributions
of any voluntary deferrals allocated at any time to the Danaher common stock investment option) will be made solely in shares
of Company common stock, and therefore are not reflected in the above amounts.
Fair Value of Financial Instruments
The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions):
October 2, 2020 December 31, 2019
Carrying
Amount Fair Value Carrying
Amount Fair Value
Assets:
Available-for-sale debt securities $ 29.6 $ 29.6 $ 33.7 $ 33.7
Investment in equity securities 235.2 235.2 110.8 110.8
Cross-currency swap derivative contracts 35.9 35.9 25.7 25.7
Liabilities:
Cross-currency swap derivative contracts 120.2 120.2 111.7 111.7
Notes payable and current portion of long-term debt 19.7 19.7 212.4 212.4
Long-term debt 21,806.1 23,019.1 21,516.7 21,896.9
As of October 2, 2020 and December 31, 2019, available-for-sale debt securities and cross-currency swap derivative contracts
were categorized as Level 2 and short and long-term borrowings were categorized as Level 1.
The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the
carrying amounts of long-term borrowings (other than the Company’s Liquid Yield Option Notes due 2021 (the “LYONs”)) is
attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the
borrowing. In the case of the LYONs, differences in the fair value from the carrying value are attributable to changes in the
price of the Company’s common stock due to the LYONs’ conversion features. The fair values of borrowings with original
maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable
approximate their carrying amounts due to the short-term maturities of these instruments.
Table of Contents
17

-- 20 of 73 --

NOTE 7. FINANCING
As of October 2, 2020, the Company was in compliance with all of its debt covenants. The components of the Company’s debt
were as follows ($ in millions):
October 2, 2020 December 31, 2019
Euro-denominated commercial paper (€1.6 billion and €4.6 billion, respectively) $ 1,860.8 $ 5,146.2
Zero-coupon LYONs due 2021 26.2 33.6
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the
“2021 Yen Notes”) 284.6 275.8
1.7% senior unsecured notes due 2022 (€800 million aggregate principal amount) (the “2022
Euronotes”) 935.5 894.8
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount)
(the “Floating Rate 2022 Euronotes”) 292.4 279.8
2.05% senior notes due 2022 (the “2022 Biopharma Notes”) 697.8 696.9
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the
“2023 CHF Bonds”) 587.3 558.9
1.7% senior unsecured notes due 2024 (€900.0 million aggregate principal amount) (the
“2024 Euronotes”) 1,049.4 —
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”) 696.6 696.2
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the
“2025 Euronotes”) 934.0 893.7
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”) 497.6 497.3
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026
Biopharma Euronotes”) 1,455.5 1,392.3
2.1% senior unsecured notes due 2026 (€800.0 million aggregate principal amount) (the
“2026 Euronotes”) 933.3 —
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027
Yen Notes”) 291.4 282.5
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the
“2027 Euronotes”) 698.4 668.0
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028
Biopharma Euronotes”) 1,453.6 1,390.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount)
(the “2028 CHF Bonds”) 231.8 221.0
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”) 794.6 794.8
2.5% senior unsecured notes due 2030 (€800.0 million aggregate principal amount) (the
“2030 Euronotes”) 936.8 —
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031
Biopharma Euronotes”) 2,037.0 1,948.7
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032
Yen Notes”) 503.1 487.8
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039
Biopharma Euronotes”) 1,446.6 1,383.6
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”) 889.2 890.3
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”) 499.4 499.4
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the
“2049 Biopharma Euronotes”) 868.6 830.9
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”) 888.6 890.2
Other 35.7 76.3
Total debt 21,825.8 21,729.1
Less: currently payable 19.7 212.4
Long-term debt $ 21,806.1 $ 21,516.7
For additional details regarding the Company’s debt financing, refer to Note 11 of the Company’s financial statements as of and
for the year ended December 31, 2019 included in the Company’s 2019 Annual Report.
Table of Contents
18

-- 21 of 73 --

The Company has historically satisfied any short-term liquidity needs that are not met through operating cash flow and
available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper
programs. The Company’s $5.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on
August 24, 2024 (the “Five-Year Facility”) and the Company’s $2.5 billion 364-day unsecured revolving credit facility with a
syndicate of banks (the “364-Day Facility” and collectively with the Five-Year Facility, the “Credit Facilities”) that expires on
June 4, 2021 (the “Scheduled Termination Date”) are available for direct borrowings and provide support for the commercial
paper programs (on June 5, 2020, the 364-Day Facility replaced the $5.0 billion 364-day unsecured revolving credit facility
with a syndicate of banks that was scheduled to expire on August 26, 2020 (the “Superseded 364-Day Facility”)).
Given the adverse impact of COVID-19 on the availability of new borrowings in the commercial paper markets late in the first
quarter and in the second quarter of 2020, the Company borrowed under the Five-Year Facility and the Superseded 364-Day
Facility during the first and second quarters of 2020. Specifically, on March 24, 2020, the Company borrowed $2.5 billion
under the Five-Year Facility to fund a portion of the Cytiva Acquisition and for general corporate purposes, at an annual
interest rate of 1.7% through March 31, 2020 and 1.9% beginning April 1, 2020. On April 7, 2020, the Company borrowed
$2.5 billion under the Superseded 364-Day Facility for general corporate purposes at an annual interest rate of 2.3%. On May
15, 2020, the Company repaid the borrowings under the Superseded 364-Day Facility and $1.25 billion of outstanding
borrowings under the Five-Year Facility. On September 24, 2020, the Company repaid the remaining $1.25 billion of
outstanding borrowings under the Five-Year Facility. As of October 2, 2020, the Company was in compliance with all
covenants under the Credit Facilities. The Company expects to limit borrowings under the Five-Year Facility and 364-Day
Facility to amounts that would leave sufficient borrowing capacity under the facilities so that it could borrow, if needed, to
repay all of the outstanding commercial paper as it matures.
On October 6, 2020, the Company notified the holders of the 2022 Euronotes that it has called for redemption all of the
€800 million aggregate principal amount of the 2022 Euronotes and intends to redeem the 2022 Euronotes on November 5,
2020. The Company has classified the 2022 Euronotes, LYONs, the 2021 Yen Notes and approximately $1.9 billion of its
borrowings outstanding under the commercial paper programs as of October 2, 2020 as long-term debt in the accompanying
Consolidated Condensed Balance Sheet as the Company had the intent and ability, as supported by availability under the Five-
Year Facility and the Company’s fourth quarter long-term debt issuance (refer to Note 16), to refinance these borrowings for at
least one year from the balance sheet date.
As of October 2, 2020, borrowings outstanding under the Company’s euro-denominated commercial paper program had a
weighted average annual interest rate of negative 0.08% and a weighted average remaining maturity of approximately 60 days.
Debt discounts, premiums and debt issuance costs totaled $116 million and $112 million as of October 2, 2020 and
December 31, 2019, respectively, and have been netted against the aggregate principal amounts of the related debt in the
components of debt table above.
2020 Debt Issuances
On March 30, 2020 and April 8, 2020, Danaher Corporation completed underwritten public offerings of senior unsecured
Euronotes due 2024, 2026 and 2030 (collectively the “Notes”). The following summarizes the key terms of the offerings in
aggregate (€ in millions):
Issue Date
Aggregate
Principal
Amount Stated Annual
Interest Rate
Issue Price (as
% of Principal
Amount) Maturity Date
Interest Payment
Dates
(in arrears)
2024 Euronotes March 30, 2020 € 750.0 1.700 % 99.931 % March 30, 2024 March 30
2024 Euronotes April 8, 2020 € 150.0 1.700 % 100.298 % March 30, 2024 March 30
2026 Euronotes March 30, 2020 € 500.0 2.100 % 99.717 % September 30, 2026 September 30
2026 Euronotes April 8, 2020 € 300.0 2.100 % 100.842 % September 30, 2026 September 30
2030 Euronotes March 30, 2020 € 500.0 2.500 % 99.642 % March 30, 2030 March 30
2030 Euronotes April 8, 2020 € 300.0 2.500 % 102.166 % March 30, 2030 March 30
The Company received net proceeds from the notes issued on March 30, 2020, after underwriting discounts and commissions
and offering expenses, of approximately €1.7 billion (approximately $1.9 billion based on currency exchange rates as of the
date of the pricing of the notes). The Company received net proceeds from the notes issued on April 8, 2020, after underwriting
discounts and commissions and offering expenses, of €754 million ($816 million based on currency exchange rates as of the
date of the pricing of the notes). Proceeds from these offerings have been and will be used for general corporate purposes,
including repayment of a portion of the Company’s outstanding commercial paper borrowings as they mature and repayment of
amounts borrowed under the Company’s Credit Facilities.
Table of Contents
19

-- 22 of 73 --

On October 6, 2020 (during the Company’s fourth quarter), the Company completed the underwritten public offering of $1.0
billion aggregate principal amount of 2.6% senior unsecured notes due 2050. The Company received net proceeds from the
notes, after underwriting discounts and commissions and offering expenses, of $980 million. Proceeds from this offering will
be used for general corporate purposes, including the redemption of the 2022 Euronotes.
Credit Facilities
For a description of the Five-Year Facility, please see the Company’s 2019 Annual Report.
On June 5, 2020, the Company entered into the 364-Day Facility. The Company may elect, upon the payment of a fee equal to
0.75% of the principal amount of the loans then outstanding and upon the satisfaction of certain conditions, to convert any loans
outstanding on the Scheduled Termination Date into term loans that are due and payable one year following the Scheduled
Termination Date.
Borrowings under the 364-Day Facility bear interest as follows: (1) Eurodollar Rate Loans (as defined in the 364-Day Facility)
bear interest at a variable rate per annum equal to the London inter-bank offered rate plus a margin of between 90.0 and 127.5
basis points, depending on Danaher’s long-term debt credit rating; and (2) Base Rate Loans (as defined in the 364-Day Facility)
bear interest at a variable rate per annum equal to the highest of (a) the Federal funds rate (as published by the Federal Reserve
Bank of New York from time to time) plus 0.5%, (b) Bank of America’s “prime rate” as publicly announced from time to time
and (c) the Eurodollar Rate (as defined in the 364-Day Facility) plus 1.0%, plus in each case a margin of between 0.0 and 27.5
basis points depending on Danaher’s long-term debt credit rating. In addition, Danaher is required to pay a per annum facility
fee of between 10.0 and 22.5 basis points (depending on Danaher’s long-term debt credit rating) based on the aggregate
commitments under the 364-Day Facility, regardless of usage.
The Company’s obligations under the 364-Day Facility are unsecured. The Company has unconditionally and irrevocably
guaranteed the obligations of each of its subsidiaries in the event a subsidiary is named a borrower under the 364-Day Facility.
The 364-Day Facility contains customary representations, warranties, conditions precedent, events of default, indemnities and
affirmative and negative covenants. The 364-Day Facility requires the Company to maintain a Consolidated Leverage Ratio (as
defined in the 364-Day Facility) of 0.65 to 1.00 or less. Borrowings under the 364-Day Facility are prepayable at the
Company’s option at any time in whole or in part without premium or penalty.
Guarantors of Debt
The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The
2022 Euronotes, Floating Rate 2022 Euronotes, 2025 Euronotes, 2027 Euronotes and euro-denominated commercial paper were
issued by DH Europe Finance S.A. (“Danaher International”). The 2022 Biopharma Notes, 2024 Biopharma Notes, 2026
Biopharma Euronotes, 2028 Biopharma Euronotes, 2029 Biopharma Notes, 2031 Biopharma Euronotes, 2039 Biopharma
Euronotes, 2049 Biopharma Euronotes, 2049 Biopharma Notes and euro-denominated commercial paper were issued by DH
Europe Finance II S.a.r.l. (“Danaher International II”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH
Switzerland Finance S.A. (“Danaher Switzerland”). The 2021 Yen Notes, 2027 Yen Notes and 2032 Yen Notes were issued by
DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher International II, Danaher Switzerland and
Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the outstanding and future securities
issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these guarantees rank
on parity with the Company’s unsecured and unsubordinated indebtedness.
LYONs Redemption
During the nine-month period ended October 2, 2020, holders of certain of the Company’s LYONs converted such LYONs into
an aggregate of 294 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s deferred tax
liability of $42 million associated with the book and tax basis difference in converted LYONs was transferred to additional
paid-in capital.
NOTE 8. HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company uses cross-currency swap derivative contracts to partially hedge its net investments in foreign operations against
adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The
cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate
payments in another currency. As of October 2, 2020, the Company had $2.0 billion, including $1.0 billion entered into during
the three-month period ended October 2, 2020, of cross-currency swap derivative contracts outstanding as hedges of its net
investment in foreign operations. These contracts effectively convert U.S. dollar-denominated bonds to obligations
denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of changes in currency rates
Table of Contents
20

-- 23 of 73 --

on the Company’s foreign currency denominated net investments. These contracts also reduce the interest rate from the stated
interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The changes in the spot rate of these
instruments are recorded in accumulated other comprehensive income (loss) in stockholders’ equity, partially offsetting the
foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other
comprehensive income (loss) in the accompanying Consolidated Condensed Statements of Stockholders’ Equity. Any
ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into
earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense in the
accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense
attributable to the underlying debt. These instruments mature on dates ranging from September 2025 to October 2030.
The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in
a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates between the U.S. dollar
and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The
changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss) in stockholders’
equity, with a reclassification from accumulated other comprehensive income (loss) to net earnings to offset the remeasurement
of the hedged debt that is also recorded in net earnings. Any ineffective portions of net investment hedges are reclassified from
accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense
from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings
consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates
ranging from November 2022 to November 2049.
The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in foreign
operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen and Swiss franc.
These foreign currency denominated long-term debt issuances are designated and qualify as nonderivative hedging instruments.
Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated other comprehensive income
(loss) in stockholders’ equity in the accompanying Consolidated Condensed Balance Sheets, offsetting the foreign currency
translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive
income (loss). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive
income (loss) into earnings during the period of change. These instruments mature on dates ranging from March 2021 to May
2032.
The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark interest
rates related to a portion of the U.S. debt the Company issued to fund the Cytiva Acquisition. These contracts effectively fixed
the interest rate for a portion of the Company’s U.S. dollar-denominated debt equal to the notional amount of the swaps to the
rate specified in the interest rate swap agreements and were settled in November 2019. The changes in the fair value of these
instruments were recorded in accumulated other comprehensive income (loss) in stockholders’ equity prior to the issuance of
the debt and are subsequently being reclassified to interest expense over the life of the related debt.
Table of Contents
21

-- 24 of 73 --

The following table summarizes the notional values as of October 2, 2020 and pretax impact of changes in the fair values of
instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for
the three and nine-month periods ended October 2, 2020 and September 27, 2019 ($ in millions):
Original
Notional Amount Notional Amount
Outstanding
Gain (Loss)
Recognized in
OCI
For the Three-Month Period Ended October 2, 2020:
Net investment hedges:
Foreign currency contracts $ 2,875.0 $ 2,000.0 $ (57.6)
Foreign currency denominated debt 6,619.3 6,619.3 (208.4)
Cash flow hedges:
Foreign currency contracts 4,000.0 4,000.0 (304.9)
Total $ 13,494.3 $ 12,619.3 $ (570.9)
For the Three-Month Period Ended September 27, 2019:
Net investment hedges:
Foreign currency contracts: $ 2,525.0 $ 1,650.0 $ 41.5
Foreign currency denominated debt 8,073.6 8,073.6 255.2
Cash flow hedges:
Interest rate swaps 1,500.0 1,500.0 (55.1)
Total $ 12,098.6 $ 11,223.6 $ 241.6
For the Nine-Month Period Ended October 2, 2020:
Net investment hedges:
Foreign currency contracts: $ 2,875.0 $ 2,000.0 $ 10.1
Foreign currency denominated debt 6,619.3 6,619.3 (241.5)
Cash flow hedges:
Foreign currency contracts 4,000.0 4,000.0 (8.4)
Total $ 13,494.3 $ 12,619.3 $ (239.8)
For the Nine-Month Period Ended September 27, 2019:
Net investment hedges:
Foreign currency contracts $ 2,525.0 $ 1,650.0 $ 36.8
Foreign currency denominated debt 8,073.6 8,073.6 263.5
Cash flow hedges:
Interest rate swaps 1,500.0 1,500.0 (64.0)
Total $ 12,098.6 $ 11,223.6 $ 236.3
Gains or losses related to net investment hedges are classified as foreign currency translation adjustments in the schedule of
changes in OCI in Note 1, as these items are attributable to the Company’s hedges of its net investment in foreign operations.
Gains or losses related to the cash flow hedges and interest rate swaps are classified as cash flow hedge adjustments in the
schedule of changes in OCI in Note 1. The amount reclassified to earnings for the interest rate swaps in the three and nine-
month periods ended October 2, 2020 were $1 million and $2 million, respectively. During the three and nine-month periods
ended October 2, 2020, the Company reclassified $167 million and $183 million, respectively, of deferred losses from
accumulated other comprehensive income (loss) to net earnings related to the cross-currency swap derivative contracts that are
cash flow hedges of the Company’s U.S. dollar-denominated debt. This reclassification was equal to the remeasurement gain
recorded in the three and nine-month periods on the hedged debt.
The Company did not reclassify any other deferred gains or losses related to net investment hedges or cash flow hedges from
accumulated other comprehensive income (loss) to earnings during the three and nine-month periods ended October 2, 2020
and September 27, 2019. In addition, the Company did not have any ineffectiveness related to net investment hedges or interest
Table of Contents
22

-- 25 of 73 --

rate swaps during the three and nine-month periods ended October 2, 2020 and September 27, 2019. The cash inflows and
outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in all other
investing activities in the accompanying Consolidated Condensed Statements of Cash Flows. The cash inflows and outflows
associated with the Company’s derivative contracts designated as cash flow hedges are classified in cash flows from operating
activities in the accompanying Consolidated Condensed Statements of Cash Flows.
The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net
investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions):
October 2, 2020 December 31, 2019
Derivative assets:
Prepaid expenses and other current assets $ — $ 25.7
Other long-term assets 35.9 —
Derivative liabilities:
Accrued expenses and other liabilities 120.2 111.7
Nonderivative hedging instruments:
Long-term debt 6,619.3 6,275.9
Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive income (loss)
to net earnings during the next 12 months if interest rates and foreign exchange rates remain the same are not significant.
NOTE 9. DEFINED BENEFIT PLANS
The following sets forth the components of the Company’s net periodic benefit (cost) of the noncontributory defined benefit
pension plans ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
U.S. pension benefits:
Service cost $ — $ (1.6) $ — $ (4.8)
Interest cost (17.3) (22.1) (51.2) (66.5)
Expected return on plan assets 30.1 31.0 89.7 94.2
Amortization of actuarial loss (9.5) (6.7) (27.6) (19.1)
Amortization of prior service cost (0.2) (0.2) (0.7) (0.7)
Net periodic pension benefit $ 3.1 $ 0.4 $ 10.2 $ 3.1
Non-U.S. pension benefits:
Service cost $ (10.9) $ (6.0) $ (27.7) $ (17.6)
Interest cost (6.0) (6.1) (16.2) (18.4)
Expected return on plan assets 9.1 10.0 26.9 30.2
Amortization of actuarial loss (2.4) (1.1) (7.1) (3.3)
Amortization of prior service credit 0.2 — 0.8 0.1
Curtailment gain recognized — — 0.4 —
Settlement gain recognized — 0.1 — —
Net periodic pension cost $ (10.0) $ (3.1) $ (22.9) $ (9.0)
Table of Contents
23

-- 26 of 73 --

The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee
benefit plans ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Service cost $ (0.1) $ (0.1) $ (0.3) $ (0.3)
Interest cost (0.9) (1.3) (2.6) (3.8)
Amortization of actuarial loss (0.3) — (0.3) —
Amortization of prior service credit 0.6 0.6 1.7 1.6
Net periodic cost $ (0.7) $ (0.8) $ (1.5) $ (2.5)
The net periodic benefit cost of the noncontributory defined benefit pension plans and other postretirement employee benefit
plans incurred during the three and nine-month periods ended October 2, 2020 and September 27, 2019 are reflected in the
following captions in the accompanying Consolidated Condensed Statements of Earnings ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Service cost:
Cost of sales $ (2.9) $ (2.0) $ (7.2) $ (6.2)
Selling, general and administrative expenses (8.1) (5.7) (20.8) (16.5)
Total service cost (11.0) (7.7) (28.0) (22.7)
Other net periodic benefit costs:
Other (expense) income, net 3.4 4.2 13.8 14.3
Total $ (7.6) $ (3.5) $ (14.2) $ (8.4)
Employer Contributions
During 2020, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are
forecasted to be approximately $85 million and $50 million, respectively. The ultimate amounts to be contributed depend upon,
among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of
the contribution, local practices, market conditions, interest rates and other factors. On March 27, 2020, the Coronavirus Aid,
Relief, and Economic Security (“CARES”) Act was signed into law and includes a provision that allows employers to defer
payment of contributions to U.S. defined benefit pension plans due in 2020 until January 1, 2021. The Company has not
elected to defer any 2020 contributions to its U.S. defined benefit pension plans pursuant to this provision.
NOTE 10. INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Effective tax rate 13.5 % 19.8 % 18.5 % 29.6 %
The effective tax rate for the three-month period ended October 2, 2020 differs from the U.S. federal statutory rate of 21.0%
principally due to the release of reserves for uncertain tax positions from audit settlements and expiration of statutes of
limitation, excess tax benefits from stock-based compensation and other items. These items decreased the reported tax rate on a
net basis by 6.1%.
The effective tax rate for the nine-month period ended October 2, 2020 differs from the U.S. federal statutory rate of 21.0%
principally due to release of reserves for uncertain tax positions from audit settlements and expiration of statutes of limitation
and excess tax benefits from stock-based compensation, partially offset by a higher tax rate associated with the gain on the
divestiture of certain product lines in the Life Sciences segment in the second quarter of 2020 and changes in estimates
associated with prior period uncertain tax positions. These items decreased the reported tax rate on a net basis by 1.1%.
The effective tax rate for the three-month period ended September 27, 2019 differs from the U.S. federal statutory rate of 21.0%
principally due to the impact of earnings outside the United States which generally are taxed at rates lower than the U.S. federal
rate.
Table of Contents
24

-- 27 of 73 --

The effective tax rate for the nine-month period ended September 27, 2019 differs from the U.S. federal statutory rate of 21.0%
principally due to the impact of net discrete charges of $227 million ($0.31 per diluted common share) related primarily to
changes in estimates associated with prior period uncertain tax positions and audit settlements, net of the release of reserves for
uncertain tax positions due to the expiration of statutes of limitation, release of valuation allowances associated with certain
foreign tax credits, tax benefits resulting from changes in tax law and excess tax benefits from stock-based compensation.
These net discrete income tax charges increased the reported tax rate by 9.7%.
In the fourth quarter of 2018 and in the first quarter of 2019, the Internal Revenue Service (“IRS”) proposed significant
adjustments to the Company’s taxable income for the years 2012 through 2015 with respect to the deferral of tax on certain
premium income related to the Company’s self-insurance programs. For income tax purposes, the recognition of premium
income has been deferred in accordance with U.S. tax laws related to insurance. The IRS challenged the deferral of premiums
for certain types of the Company’s self-insurance policies. These proposed adjustments would have increased the Company’s
taxable income over the 2012 through 2015 period by approximately $2.7 billion. In the third quarter of 2020, the Company
settled the 2012 through 2015 audit period with the IRS, including the resolution of these proposed adjustments. The settlement
was not material to the Company’s financial statements, including its cash flows and effective tax rate. As the settlement with
the IRS was specific to the audit period, the settlement does not preclude the IRS from proposing similar adjustments to the
Company’s self-insurance programs in current or future audits. In connection with its examination of the Company’s federal
income tax returns for 2016, 2017 and 2018, the IRS has requested additional information on the Company’s self-insurance
programs. Due to the enactment of the Tax Cuts and Jobs Act in 2017 and the resulting reduction in the U.S. corporate tax rate
for years after 2017, the Company revalued its deferred tax liabilities related to the temporary differences associated with this
deferred premium income from 35.0% to 21.0%. If the IRS proposes adjustments related to the Company’s self-insurance
premiums with respect to years subsequent to 2015 and the Company is unsuccessful in defending its position, any taxes owed
to the IRS may be computed under the previous 35.0% statutory tax rate and the Company may be required to revalue the
related deferred tax liabilities from 21.0% to 35.0%, which in addition to any interest due on the amounts assessed, would
require a charge to future earnings. Management believes the positions the Company has taken in its U.S. tax returns are in
accordance with the relevant tax laws.
Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries.
On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) of approximately DKK
1.9 billion including interest (approximately $292 million based on the exchange rate as of October 2, 2020), imposing
withholding tax relating to interest accrued in Denmark on borrowings by certain of the Company’s subsidiaries for the years
2004-2009. The Company appealed these assessments to the Danish National Tax Tribunal in 2014. The appeal is pending,
awaiting the final outcome of other, preceding withholding tax cases that were appealed to the Danish Courts and subsequently
to the Court of Justice of the European Union (“CJEU”). In February 2019, the CJEU decided several of these cases and ruled
that the exemption of interest payments from withholding taxes provided in the applicable European Union (“EU”) directive
should be denied where taxpayers use the directive for abusive or fraudulent purposes, and that it is up to the national courts to
make this determination. This decision of the CJEU now awaits application by the Danish High Court in the other, preceding
withholding tax cases. SKAT has maintained a similar position related to withholding tax on interest accrued in Denmark on
borrowings by certain of the Company’s subsidiaries with respect to tax years 2010-2012 and 2013-2015. On August 27, 2019
and December 16, 2019, the Company received assessments for these matters of approximately DKK 1.1 billion including
interest (approximately $169 million based on the exchange rate as of October 2, 2020) for tax years 2010-2012 and DKK 761
million including interest (approximately $120 million based on the exchange rate as of October 2, 2020) for tax years
2013-2015, respectively. The Company is appealing these assessments as well.
Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is
vigorously defending its positions. The Company intends on pursuing this matter through the Danish High Court should the
appeal to the Danish National Tax Tribunal be unsuccessful. The Company will continue to monitor decisions of both the
Danish courts and the CJEU and evaluate the impact of these court rulings on the Company’s tax positions in Denmark. The
ultimate resolution of this matter is uncertain, could take many years, and could result in a further material adverse impact to the
Company’s financial statements, including its cash flow and effective tax rate.
On June 24, 2020, SKAT issued a press release to announce that it has misapplied Denmark’s interest rules in some
assessments concerning withholding tax. The Company’s subsidiaries in Denmark have been notified that they may be one of
the companies potentially overcharged interest but a determination of the impact of such notice has not been received.
Table of Contents
25

-- 28 of 73 --

NOTE 11. OTHER (EXPENSE) INCOME, NET AND GAIN ON SALE OF PRODUCT LINES
The Company disaggregates the service cost component of net periodic benefit costs of the noncontributory defined benefit
pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in
other (expense) income, net. These other components include the assumed rate of return on plan assets, partially offset by
amortization of actuarial losses and interest and aggregated to a gain of $3 million and $14 million for the three and nine-month
periods ended October 2, 2020, respectively, compared to a gain of $4 million and $14 million for the three and nine-month
periods ended September 27, 2019, respectively.
The Company estimates the fair value of investments in equity securities using the Fair Value Alternative and records
adjustments to fair value within net earnings. Additionally, the Company is a limited partner in a partnership that invests in
early stage companies. While the partnership records these investments at fair value, the Company’s investment in the
partnership is accounted for under the equity method of accounting. During the three and nine-month periods ended October 2,
2020, the Company recorded unrealized gains of $3 million and unrealized losses of $10 million, respectively, related to
changes in the fair value of these investments. No significant realized or unrealized gains or losses were recorded in the three
and nine-month periods ended September 27, 2019 with respect to these investments.
As a condition to obtaining certain regulatory approvals for the closing of the Cytiva Acquisition, the Company was required to
divest certain of its existing product lines in the Life Sciences segment that in the aggregate generated revenues of
approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of these product lines for a cash
purchase price, net of cash transferred and transaction costs, of $826 million and recognized a pretax gain on sale of $455
million ($305 million after-tax or $0.42 per diluted common share) in the second quarter of 2020. The divestiture of these
product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and
therefore is not reported as a discontinued operation.
NOTE 12. COMMITMENTS AND CONTINGENCIES
The Company reviews the adequacy of its legal reserves on a quarterly basis and establishes reserves for loss contingencies that
are both probable and reasonably estimable. For a further description of the Company’s litigation and contingencies, refer to
Note 18 of the Company’s financial statements as of and for the year ended December 31, 2019 included in the Company’s
2019 Annual Report.
The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted
against defects in material and workmanship when properly used for their intended purpose, installed correctly and
appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale up to ten
years. The amount of the accrued warranty liability is determined based on historical information such as past experience,
product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated
property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information
regarding expected warranty costs becomes known.
The following is a rollforward of the Company’s accrued warranty liability ($ in millions):
Balance, December 31, 2019 $ 73.3
Accruals for warranties issued during the period 33.1
Settlements made (26.3)
Adjustments due to acquisitions/divestitures 1.7
Effect of foreign currency translation 0.4
Balance, October 2, 2020 $ 82.2
NOTE 13. STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION
Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the nine-month
period ended October 2, 2020. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the
“Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to
time on the open market or in privately negotiated transactions. As of October 2, 2020, 20 million shares remained available
for repurchase pursuant to the Repurchase Program.
Table of Contents
26

-- 29 of 73 --

The following table summarizes the Company’s share activity (shares in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Preferred stock - shares issued:
Balance, beginning of period 3.4 1.7 1.7 —
Issuance of MCPS — — 1.7 1.7
Balance, end of period 3.4 1.7 3.4 1.7
Common stock - shares issued:
Balance, beginning of period 849.5 834.0 835.5 817.9
Common stock-based compensation awards 1.1 1.0 3.9 4.1
Common stock issued in connection with
LYONs’ conversions — — 0.3 0.9
Issuance of common stock — — 10.9 12.1
Balance, end of period 850.6 835.0 850.6 835.0
In May 2020, the Company completed the underwritten public offering of 10.9 million shares of Danaher common stock at a
price to the public of $163.00 per share (the “2020 Common Stock Offering”), resulting in net proceeds of approximately $1.73
billion, after deducting expenses and the underwriters’ discount of $54 million. Simultaneously, the Company completed the
underwritten public offering of 1.72 million shares of its 5.0% Series B Mandatory Convertible Preferred Stock (“MCPS Series
B”), without par value and with a liquidation preference of $1,000 per share (the “2020 MCPS Offering”), resulting in net
proceeds of approximately $1.67 billion, after deducting expenses and the underwriters’ discount of $49 million. The Company
has used and intends to use the net proceeds from the 2020 Common Stock Offering and the 2020 MCPS Offering for general
corporate purposes and pending such use has invested the net proceeds in short-term bank deposits and/or interest-bearing,
investment-grade securities.
On March 1, 2019, the Company completed the underwritten public offering of 12.1 million shares of Danaher common stock
at a price to the public of $123.00 per share (the “2019 Common Stock Offering”), resulting in net proceeds of approximately
$1.4 billion, after deducting expenses and the underwriters’ discount of $45 million. Simultaneously, the Company completed
the underwritten public offering of 1.65 million shares of its 4.75% MCPS Series A, without par value and with a liquidation
preference of $1,000 per share (the “2019 MCPS Offering”), resulting in net proceeds of approximately $1.6 billion, after
deducting expenses and the underwriters’ discount of $50 million. The Company used the net proceeds from the 2019
Common Stock Offering and the 2019 MCPS Offering to fund a portion of the cash consideration payable for, and certain costs
associated with, the Cytiva Acquisition. Prior to the completion of the Cytiva Acquisition, the Company invested the net
proceeds in short-term bank deposits and/or interest-bearing, investment-grade securities.
Unless converted earlier in accordance with the terms of the applicable certificate of designations, each share of MCPS Series A
and MCPS Series B (together, the “MCPS Shares”) will mandatorily convert on their respective Mandatory Conversion Date,
set forth below, into a number of shares of the Company’s common stock between the applicable Minimum Conversion Rate
and the applicable Maximum Conversion Rate, set forth below, subject to further anti-dilution adjustments. The number of
shares of the Company’s common stock issuable upon conversion will be determined based on the average volume-weighted
average price per share of the Company’s common stock over the 20 consecutive trading day period beginning on, and
including, the 21st scheduled trading day immediately before the applicable Mandatory Conversion Date. Subject to certain
exceptions, at any time prior to the Mandatory Conversion Date, holders may elect to convert the MCPS Shares into common
stock based on the applicable Minimum Conversion Rate, subject to further anti-dilution adjustments. In the event of a
fundamental change, the MCPS Shares will convert at the fundamental change rates specified in the applicable certificate of
designations, and the holders of MCPS Shares would be entitled to a fundamental change make-whole dividend. In the third
quarter of 2020, nine shares of MCPS Series A were converted into 59 shares of Danaher common stock.
Holders of MCPS Shares will be entitled to receive, when and if declared by the Company’s Board of Directors, cumulative
dividends at the applicable Annual Cumulative Dividend Rate of the Liquidation Preference per share, payable in cash or,
subject to certain limitations, by delivery of shares of the Company’s common stock or any combination of cash and shares of
the Company’s common stock, at the Company’s election. If declared, dividends on the MCPS Shares are payable quarterly on
January 15, April 15, July 15 and October 15 of each year (to, and including, the Mandatory Conversion Date), to the holders of
record of the MCPS Shares as they appear on the Company’s stock register at the close of business on the immediately
preceding December 31, March 31, June 30 and September 30, respectively.
Table of Contents
27

-- 30 of 73 --

The following summarizes the key terms of the MCPS Shares:
Annual Cumulative
Dividend Rate Liquidation
Preference per share Minimum
Conversion Rate Maximum
Conversion Rate Mandatory
Conversion Date
Series A 4.75 % $ 1,000 6.6556 shares 8.1530 shares April 15, 2022
Series B 5.00 % $ 1,000 5.0081 shares 6.1349 shares April 15, 2023
For a full description of the Company’s stock-based compensation programs, refer to Note 19 of the Company’s financial
statements as of and for the year ended December 31, 2019 included in the Company’s 2019 Annual Report. As of October 2,
2020, approximately 54 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus
Incentive Plan.
The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Restricted stock units (“RSUs”)/performance stock
units (“PSUs”):
Pretax compensation expense $ 27.6 $ 25.4 $ 83.2 $ 72.0
Income tax benefit (5.9) (5.3) (17.2) (14.9)
RSU/PSU expense, net of income taxes 21.7 20.1 66.0 57.1
Stock options:
Pretax compensation expense 17.7 15.6 53.9 45.5
Income tax benefit (3.6) (3.4) (11.0) (9.5)
Stock option expense, net of income taxes 14.1 12.2 42.9 36.0
Total stock-based compensation:
Pretax compensation expense 45.3 41.0 137.1 117.5
Income tax benefit (9.5) (8.7) (28.2) (24.4)
Total stock-based compensation expense, net of
income taxes $ 35.8 $ 32.3 $ 108.9 $ 93.1
Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the
accompanying Consolidated Condensed Statements of Earnings. As of October 2, 2020, $195 million of total unrecognized
compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two
years. As of October 2, 2020, $183 million of total unrecognized compensation cost related to stock options is expected to be
recognized over a weighted average period of approximately three years. Future compensation amounts will be adjusted for
any changes in estimated forfeitures.
NOTE 14. NET EARNINGS PER COMMON SHARE FROM CONTINUING OPERATIONS
Basic net earnings per common share (“EPS”) from continuing operations is calculated by taking net earnings from continuing
operations less the MCPS dividends divided by the weighted average number of common shares outstanding for the applicable
period. Diluted net EPS from continuing operations is computed by taking net earnings from continuing operations plus the
interest on the Company’s LYONs less the MCPS dividends divided by the weighted average number of common shares
outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common
shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the
issuance of the potentially dilutive shares. For the three-month period ended October 2, 2020, no options to purchase shares
were excluded from the diluted EPS calculation. For the nine-month period ended October 2, 2020, approximately 1 million
options to purchase shares were not included in the diluted EPS calculation as the impact of their inclusion would have been
anti-dilutive. For the three and nine-month periods ended September 27, 2019, no options to purchase shares were excluded
from the diluted EPS calculation. Basic and diluted EPS are computed independently for each quarter and year-to-date period,
which involves the use of different weighted-average share count figures relating to quarterly and annual periods. As a result,
and after factoring the effect of rounding to the nearest cent per share, the sum of prior quarter-to-date EPS figures may not
equal year-to-date EPS.
The impact of the MCPS Shares calculated under the if-converted method was anti-dilutive, and as such 20 million shares and
16 million shares for the three and nine-month periods ended October 2, 2020, respectively, and 12 million shares and 9 million
shares for the three and nine-month periods ended September 27, 2019, respectively, underlying the MCPS Shares were
Table of Contents
28

-- 31 of 73 --

excluded from the diluted EPS calculation.
Information related to the calculation of net earnings from continuing operations per common share is summarized as follows ($
and shares in millions, except per share amounts):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Numerator:
Net earnings from continuing operations $ 883.5 $ 630.7 $ 2,405.9 $ 1,639.4
MCPS dividends (41.1) (19.6) (95.3) (48.8)
Net earnings from continuing operations
attributable to common stockholders for Basic EPS 842.4 611.1 2,310.6 1,590.6
Adjustment for interest on convertible debentures 0.3 0.4 0.9 1.4
Net earnings from continuing operations
attributable to common stockholders after assumed
conversions for Diluted EPS $ 842.7 $ 611.5 $ 2,311.5 $ 1,592.0
Denominator:
Weighted average common shares outstanding
used in Basic EPS 710.9 718.8 704.4 714.7
Incremental common shares from:
Assumed exercise of dilutive options and
vesting of dilutive RSUs and PSUs 12.4 9.1 11.3 8.9
Assumed conversion of the convertible
debentures 1.0 1.4 1.1 1.6
Weighted average common shares outstanding
used in Diluted EPS 724.3 729.3 716.8 725.2
Basic EPS from continuing operations $ 1.18 $ 0.85 $ 3.28 $ 2.23
Diluted EPS from continuing operations $ 1.16 $ 0.84 $ 3.22 $ 2.20
NOTE 15. SEGMENT INFORMATION
The Company operates and reports its results in three separate business segments consisting of the Life Sciences, Diagnostics,
and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated
operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues
less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in
the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of
reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at
consolidated totals.
Table of Contents
29

-- 32 of 73 --

Segment results are shown below ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales:
Life Sciences $ 2,922.5 $ 1,695.6 $ 7,215.3 $ 5,035.1
Diagnostics 1,889.1 1,601.9 5,176.3 4,757.0
Environmental & Applied Solutions 1,071.6 1,080.5 3,132.1 3,250.6
Total $ 5,883.2 $ 4,378.0 $ 15,523.7 $ 13,042.7
Operating profit:
Life Sciences $ 504.9 $ 342.5 $ 1,242.9 $ 995.5
Diagnostics 408.0 266.0 952.4 782.0
Environmental & Applied Solutions 245.1 256.5 707.0 761.3
Other (70.4) (88.7) (272.6) (231.1)
Total $ 1,087.6 $ 776.3 $ 2,629.7 $ 2,307.7
Segment identifiable assets are shown below ($ in millions):
October 2, 2020 December 31, 2019
Life Sciences $ 47,084.5 $ 22,381.3
Diagnostics 14,715.9 14,442.2
Environmental & Applied Solutions 4,915.4 4,881.8
Other 6,174.9 20,376.3
Total $ 72,890.7 $ 62,081.6
NOTE 16. SUBSEQUENT EVENTS
On October 6, 2020, the Company completed the underwritten public offering of $1.0 billion aggregate principal amount of
2.6% senior unsecured notes due 2050. The Company received net proceeds from the notes, after underwriting discounts and
commissions and offering expenses, of $980 million. Proceeds from this offering will be used for general corporate purposes,
including the redemption of the 2022 Euronotes.
On October 6, 2020, the Company notified the holders of the 2022 Euronotes that it has called for redemption all of the €800
million aggregate principal amount of such notes at a redemption price equal to the outstanding principal amount and a make-
whole premium as specified in the applicable indenture, plus accrued and unpaid interest. The Company intends to redeem the
2022 Euronotes on November 5, 2020. The make-whole premiums required in connection with the redemption will be
approximately €21 million (approximately $19 million after-tax based on the exchange rates as of October 2, 2020 or $0.03 per
diluted common share). The payment of the make-whole premiums will be reflected as a loss on early extinguishment of
borrowings in the Company’s fourth quarter of 2020, as the extinguishment will occur in the fourth quarter.
Table of Contents
30

-- 33 of 73 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide a
reader of Danaher Corporation’s (“Danaher,” the “Company,” “we,” “us” or “our”) financial statements with a narrative from
the perspective of Company management. The Company’s MD&A is divided into five sections:
• Information Relating to Forward-Looking Statements
• Overview
• Results of Operations
• Liquidity and Capital Resources
• Critical Accounting Estimates
You should read this discussion along with the Company’s MD&A and audited financial statements as of and for the year
ended December 31, 2019 and Notes thereto, included in the Company’s 2019 Annual Report on Form 10-K filed on February
21, 2020 (“2019 Annual Report”) and the Company’s Consolidated Condensed Financial Statements and related Notes as of
and for the three and nine-month periods ended October 2, 2020 included in this Report.
Unless otherwise indicated, all financial results in this report refer to continuing operations.
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this quarterly report, in other documents we file with or furnish to
the Securities and Exchange Commission, in our press releases, webcasts, conference calls, materials delivered to shareholders
and other communications, are “forward-looking statements” within the meaning of the United States federal securities laws.
All statements other than historical factual information are forward-looking statements, including without limitation statements
regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit
obligations and funding requirements, our liquidity position or other projected financial measures; management’s plans and
strategies for future operations, including statements relating to anticipated operating performance, cost reductions,
restructuring activities, new product and service developments, competitive strengths or market position, acquisitions and the
integration thereof (including the integration of the acquisition of the Biopharma business of General Electric Company’s
(“GE”) Life Sciences division, now known as Cytiva (the “Cytiva Acquisition”)), divestitures, spin-offs, split-offs or other
distributions, strategic opportunities, securities offerings, stock repurchases, dividends and executive compensation; growth,
declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; future
regulatory approvals and the timing and conditionality thereof; outstanding claims, legal proceedings, tax audits and
assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; the potential
or anticipated direct or indirect impact of COVID-19 on our business, results of operations and/or financial condition; general
economic and capital markets conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the
foregoing; and any other statements that address events or developments that Danaher intends or believes will or may occur in
the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,”
“project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are
intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.
Forward-looking statements are based on assumptions and assessments made by our management in light of their experience
and perceptions of historical trends, current conditions, expected future developments and other factors. Forward-looking
statements are not guarantees of future performance and actual results may differ materially from the results, developments and
business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any
such forward-looking statements. Important factors that in some cases have affected us in the past and that in the future could
cause actual results to differ materially from those envisaged in the forward-looking statements include the following:
• The COVID-19 pandemic has adversely impacted, and poses risks to, aspects of our business, results of operations and
financial condition, the nature and extent of which remain highly uncertain and unpredictable.
• The Cytiva Acquisition could negatively impact our business, results of operations and financial condition.
• Our outstanding debt has increased significantly as a result of the Cytiva Acquisition and we may incur additional debt in
the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively
Table of Contents
31

-- 34 of 73 --

impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely
affect our liquidity and financial statements.
• Conditions in the global economy, the particular markets we serve and the financial markets can adversely affect our
business and financial statements.
• Significant developments or uncertainties stemming from the U.S. administration, including changes in U.S. trade policies,
tariffs and the reaction of other countries thereto, particularly China, can have an adverse effect on our business.
• Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or
experience cyclicality.
• We face intense competition and if we are unable to compete effectively, we can experience decreased demand and
decreased market share. Even when we compete effectively, we can be required to reduce prices for our products and
services.
• Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and
enhanced products and services based on technological innovation.
• Our reputation, ability to do business and financial statements can be impaired by improper conduct by any of our
employees, agents or business partners.
• Certain of our businesses are subject to extensive regulation by the U.S. Food and Drug Administration and by comparable
agencies of other countries, as well as laws regulating fraud and abuse in the health care industry and the privacy and
security of health information. Failure to comply with those regulations can adversely affect our reputation, ability to do
business and financial statements.
• Our products are subject to clinical trials, the results of which may be unexpected, or perceived as unfavorable by the
market, and could have a material adverse effect on our business, financial condition or results of operations.
• Off-label marketing of our products could result in substantial penalties.
• Certain modifications to our products can require new 510(k) clearances or other marketing authorizations and can require
us to recall or cease marketing our products.
• The health care industry and related industries that we serve have undergone, and are in the process of undergoing,
significant changes in an effort to reduce costs, which can adversely affect our financial statements.
• Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate
investments that support our long-term strategy, could negatively impact our growth rate and stock price.
• Our acquisition of businesses, investments, joint ventures and other strategic relationships can negatively impact our
financial statements.
• The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us
and as a result we may face unexpected liabilities.
• Divestitures or other dispositions could negatively impact our business and contingent liabilities from businesses that we or
our predecessors have disposed could adversely affect our financial statements.
• We could incur significant liability if any of the 2015 separation and split-off of our communications business, the 2016
separation and spin-off of Fortive Corporation (“Fortive”) or the 2019 separation, initial public offering (“IPO”) and split-
off of Envista Holdings Corporation (“Envista”) is determined to be a taxable transaction.
• Potential indemnification liabilities pursuant to the 2015 separation and split-off of our communications business, the 2016
separation and spin-off of Fortive or the 2019 separation, IPO and split-off of Envista could materially and adversely affect
our business and financial statements.
• A significant disruption in, or breach in security of, our information technology systems or data or violation of data privacy
laws can adversely affect our business, reputation and financial statements.
• Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and
violations that can adversely affect our business, reputation and financial statements.
Table of Contents
32

-- 35 of 73 --

• Our businesses are subject to extensive regulation; failure to comply with those regulations can adversely affect our
financial statements and our business, including our reputation.
• Our restructuring actions can have long-term adverse effects on our business.
• We may be required to recognize impairment charges for our goodwill and other intangible assets.
• Foreign currency exchange rates can adversely affect our financial statements.
• Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In
addition, audits by tax authorities can result in additional tax payments for prior periods.
• Changes in tax law relating to multinational corporations could adversely affect our tax position.
• We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that can
adversely affect our business and financial statements.
• If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights,
we can suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly
pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable
to the United States.
• Third parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we
can suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
• The U.S. government has certain rights to use and disclose some of the intellectual property that we license and could
exclusively license it to a third party if we fail to achieve practical application of the intellectual property.
• Defects and unanticipated use or inadequate disclosure with respect to our products or services (including software), or
allegations thereof, can adversely affect our business, reputation and financial statements.
• The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly
encounter problems manufacturing products, our reputation, business and financial statements can suffer.
• Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels
of, key distributors and other channel partners can adversely affect our financial statements.
• Certain of our businesses rely on relationships with collaborative partners and other third parties for development, supply
and marketing of certain products and potential products, and such collaborative partners or other third parties can fail to
perform sufficiently.
• Our financial results are subject to fluctuations in the cost and availability of commodities that we use in our operations.
• If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes
in market conditions and customer demand, our profitability may suffer. In addition, our reliance upon sole or limited
sources of supply for certain materials, components and services can cause production interruptions, delays and
inefficiencies.
• Changes in laws or governmental regulations can reduce demand for our products or services or increase our expenses.
• Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and
results of operations.
• International economic, political, legal, social, compliance and business factors could negatively affect our financial
statements.
• The United Kingdom’s (“UK”) departure from the EU could have an adverse effect on us.
• If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe
or other events, our operations could be seriously harmed.
• Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements.
Table of Contents
33

-- 36 of 73 --

See Part I—Item 1A of the Company’s 2019 Annual Report and Part II—Item 1A of each of this report and the Company’s
Quarterly Report on Form 10-Q for the quarters ended April 3, 2020 (“First Quarter 2020 Form 10-Q”) and July 3, 2020
(“Second Quarter 2020 Form 10-Q”) for further discussion regarding reasons that actual results may differ materially from the
results, developments and business decisions contemplated by our forward-looking statements. Forward-looking statements
speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they
are made. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-
looking statement, whether as a result of new information, future events and developments or otherwise.
OVERVIEW
General
As a result of the Company’s geographic and industry diversity, the Company faces a variety of opportunities and challenges,
including rapid technological development (particularly with respect to computing, automation, artificial intelligence, mobile
connectivity, communications and digitization) in most of the Company’s served markets, the expansion and evolution of
opportunities in high-growth markets, trends and costs associated with a global labor force, consolidation of the Company’s
competitors and increasing regulation. The Company operates in a highly competitive business environment in most markets,
and the Company’s long-term growth and profitability will depend in particular on its ability to expand its business in high-
growth geographies and high-growth market segments, identify, consummate and integrate appropriate acquisitions, develop
innovative and differentiated new products and services with higher gross profit margins, expand and improve the effectiveness
of the Company’s sales force, continue to reduce costs and improve operating efficiency and quality, and effectively address the
demands of an increasingly regulated environment. The Company is making significant investments, organically and through
acquisitions, to address the rapid pace of technological change in its served markets and to globalize its manufacturing, research
and development and customer-facing resources (particularly in high-growth markets) in order to be responsive to the
Company’s customers throughout the world and improve the efficiency of the Company’s operations.
The COVID-19 Pandemic
The global spread of a novel strain of coronavirus (COVID-19) has led to unprecedented restrictions on, and disruptions in,
business and personal activities, including as a result of preventive and precautionary measures that we, other businesses, our
communities and governments have taken and are taking to mitigate the spread of the virus and to manage its impact. The
Company continues to actively monitor the pandemic and has taken and intends to continue taking steps to identify and mitigate
the adverse impacts on, and risks to, the Company’s business (including but not limited to its employees, customers, business
partners, manufacturing capabilities and capacity, and supply and distribution channels) posed by the spread of COVID-19 and
the governmental and community responses thereto. The Company’s businesses have activated their business continuity plans
as a result of this pandemic, including taking steps in an effort to help keep our workforce healthy and safe, and are assessing
and updating those plans on an ongoing basis. As a result of COVID-19 the Company’s businesses have modified certain of
their respective business practices (including in many cases with respect to employee travel, employee work locations, and
cancellation of physical participation in meetings, events and conferences), and the Company expects to take such further
actions as may be required by government authorities or as determined to be in the best interests of our employees, customers
and other business partners. The Company has developed return-to-work protocols designed to help ensure the health and
safety of its employees, customers and business partners, for its businesses to apply as and when return-to-work is legally
permissible and deemed appropriate. We are also working with our suppliers to understand the existing and potential future
negative impacts to our supply chain and take actions in an effort to mitigate such impacts. To date we have not experienced
any significant supply chain disruptions. Given that the prevalence of COVID-19 and the nature of the response thereto
(including the degree to which restrictions are being relaxed or re-imposed) varies significantly by geography, the impact of the
pandemic on the Company’s different business locations around the world at any given time also varies significantly.
We are also deploying our capabilities, expertise and scale to address the critical health needs related to COVID-19. We have
developed and made available a diagnostic test for the rapid detection of COVID-19 and a diagnostic test that can detect
antibodies in blood to confirm current or past exposure to COVID-19. In addition, our businesses are providing critical support
to firms that are seeking to develop and produce a vaccine for COVID-19, among other support. We estimate that COVID-19
related demand contributed approximately 1,000 basis points to core revenue growth including Cytiva in the third quarter of
2020. While we expect these trends to continue into at least the fourth quarter of 2020, as the COVID-19 pandemic subsides
we expect the demand for products and services related to COVID-19 will also subside. As further discussed below, while
COVID-19 has positively impacted revenues for certain of our businesses, the pandemic and response thereto had a material
negative impact on revenues and profitability in other of our businesses in the first nine months of 2020 and, while conditions
improved sequentially from the second quarter to the third quarter of 2020, the global demand for many of our products and
services may remain depressed at least in the near-term if not longer.
Table of Contents
34

-- 37 of 73 --

As noted below and subject to the assumptions discussed below, the Company expects core sales and core sales including
Cytiva to grow in the fourth quarter of 2020 compared to the prior year. However, due to the speed with which the COVID-19
situation continues to evolve, the global breadth of its spread, the range of governmental and community responses thereto and
our geographic and business line diversity, its further impact on our business remains highly uncertain, but may be materially
negative and will depend on future developments including but not limited to:
• the duration of the weaker macroeconomic environment and the timing and extent of recovery in the global demand
for our products and services;
• the pace at which medical providers resume patient care and testing that is not related to the COVID-19 pandemic, the
timing of when research performed by laboratories and other institutions return to normal levels, and payment and
funding dynamics related to the foregoing; and
• the development and rate of adoption of the products we are offering to help address the pandemic and the effects
thereof; competitive product launches and related pricing pressure; impacts from changes in the mix of our product
offerings; and the degree to which COVID-19 testing solutions and any vaccines are made available and utilized.
Business Performance and Outlook
During the third quarter of 2020, the Company’s overall revenues increased 34.5% compared to the comparable period of 2019.
The acquisition of Cytiva contributed 24.5% to the increase in revenues in the third quarter of 2020. Year-over-year core sales
increased 9.0% in the third quarter of 2020 compared to the prior period while core sales including Cytiva increased 14.0%
year-over-year. For the nine-month period ended October 2, 2020, overall revenues increased by 19.0%. The acquisition of
Cytiva contributed 15.5% to the increase in revenues in the nine-month period. Core sales increased 4.5% in the nine-month
period ended October 2, 2020 compared to the prior period, primarily as a result of the same factors which drove core sales for
the third quarter of 2020. For the nine-month period, core sales including Cytiva increased 7.5%, which include the results of
Cytiva beginning with the second quarter of 2020. For the definition of “core sales” and “core sales including Cytiva” refer to
“—Results of Operations” below.
Despite differences in our businesses, on an overall basis, the Company saw increased core sales growth in the third quarter, as
the performance of the Company’s businesses improved sequentially from the second quarter to the third quarter of 2020.
Geographically, the improvement generally corresponded to areas where the spread of the coronavirus and related responses
have moderated. COVID-19 related research and development among biotech and pharmaceutical customers generated strong
demand for the Company’s bioprocessing, filtration, genomic and automation solutions in the Company’s life science
businesses. Cytiva’s core sales grew more than 35% (compared to the third quarter of 2019, prior to the Cytiva Acquisition)
reflecting strength in its served markets and its support in helping its customers develop and potentially produce a vaccine for
COVID-19. In the remainder of the life sciences businesses, the Company experienced a lessening of the widespread
shutdowns that adversely impacted non-COVID related research lab activity earlier in the year and improved performance
sequentially from the second quarter to the third quarter of 2020. In its diagnostics businesses, the Company saw very strong
demand for molecular point-of-care and acute care testing, which also drove a significant increase in instrument placements
globally. While the remainder of the diagnostic businesses saw reduced demand primarily because of lower volumes of elective
procedures and wellness visits, the Company saw an improvement in patient volumes in the third quarter versus earlier in the
pandemic. In the environmental and applied solutions businesses, the divergence of demand between consumables and
equipment moderated, as demand for equipment improved sequentially from the second quarter to the third quarter of 2020.
Geographically, the Company saw increases in core sales including Cytiva in both developed markets and the high-growth
markets. Developed markets grew at a mid-teens rate during the third quarter of 2020 compared to the third quarter of 2019,
led primarily by increases in North America and Western Europe. High-growth markets increased approximately 10% during
the third quarter of 2020 as compared to the comparable period of 2019, driven primarily by increases in China and India,
partially offset by the impact of the COVID-19 pandemic and the response thereto in other high-growth markets. High-growth
markets represented approximately 31% of the Company’s total sales in the third quarter of 2020. For additional information
regarding the Company’s sales by geographical region during the three and nine-month periods ended October 2, 2020 and
September 27, 2019, refer to Note 2 to the accompanying Consolidated Condensed Financial Statements.
The Company’s net earnings from continuing operations for the three and nine-month periods ended October 2, 2020 totaled
$884 million and approximately $2.4 billion, respectively, compared to $631 million and approximately $1.6 billion for the
three and nine-month periods ended September 27, 2019. Net earnings attributable to common stockholders for the three and
nine-month periods ended October 2, 2020 totaled $842 million or $1.16 per diluted common share and approximately $2.3
billion or $3.22 per diluted common share, respectively, compared to $648 million or $0.89 per diluted common share and
approximately $1.7 billion or $2.32 per diluted common share for the three and nine-month periods ended September 27, 2019,
respectively. The provision for uncertain tax positions recorded in the first quarter of 2019 discussed below in “—Results of
Table of Contents
35

-- 38 of 73 --

Operations - Income Taxes” and 2020 net earnings from Cytiva are the primary drivers of the year-over-year increase in net
earnings and diluted net earnings per common share for the three and nine-month periods ended October 2, 2020.
While the ultimate impact of COVID-19 on future periods is highly uncertain, the Company expects core sales and core sales
including Cytiva to grow in the fourth quarter of 2020 compared to the prior year, assuming the impact of the pandemic
continues to moderate and trends in the United States and internationally with respect to stay-at-home or other quarantine
mandates do not materially deteriorate. Demand for instruments and consumables related to COVID-19-related testing
capabilities as well as supporting customers in pursuit of new COVID-19-related treatments and vaccines are expected to
continue to drive growth while the performance of the Company’s other businesses are expected to continue to improve. As
discussed above, an increase of COVID-19 related cases and the re-imposition of government required restrictions could have a
material negative impact on the Company’s core growth, earnings and cash flows.
Acquisitions
The Company’s growth strategy contemplates future acquisitions and strategic investments. Operations and results can be
affected by the rate and extent to which appropriate acquisition and investment opportunities are available and successfully
consummated, acquired businesses are effectively integrated and anticipated synergies or cost savings are achieved.
On March 31, 2020, the Company acquired the Biopharma business of General Electric Company’s Life Sciences division, now
known as Cytiva, for a cash purchase price of approximately $20.7 billion, (net of approximately $0.1 billion of acquired cash)
and the assumption of approximately $0.4 billion of pension liabilities. Cytiva is a leading provider of instruments,
consumables and software that support the research, discovery, process development and manufacturing workflows of
biopharmaceutical drugs. Cytiva is included in the Company’s Life Sciences segment results beginning in the second quarter of
2020. The acquisition has provided and is expected to provide additional sales and earnings growth opportunities for the
Company’s Life Sciences segment by expanding the business’ geographic and product line diversity, including new product
and service offerings that complement the Company’s current biologics workflow solutions. As a condition to obtaining certain
regulatory approvals for the closing of the transaction, the Company was required to divest certain of its existing product lines
in the Life Sciences segment that in the aggregate generated revenues of approximately $170 million in 2019. On April 30,
2020, the Company completed the sale of these product lines for a cash purchase price, net of cash transferred and transaction
costs, of $826 million and recognized a pretax gain on sale of $455 million ($305 million after-tax or $0.42 per diluted common
share) in the second quarter of 2020. For a description of the Company’s Cytiva Acquisition and the financing thereof, refer to
Note 3 to the accompanying Consolidated Condensed Financial Statements. In addition to the Cytiva Acquisition, during the
nine-month period ended October 2, 2020, the Company acquired one other business for total consideration of $104 million in
cash, net of cash acquired. The business acquired complements an existing unit of the Environmental & Applied Solutions
segment. The aggregate annual sales of the two businesses acquired in 2020 at the time of their acquisition, in each case based
on the companies’ revenues for its last completed fiscal year prior to the acquisition, were approximately $3.3 billion.
Currency Exchange Rates
On a year-over-year basis, currency exchange rates positively impacted reported sales by approximately 1.0% for the three-
month period ended October 2, 2020, compared to the comparable period of 2019, primarily due to the weakening of the U.S.
dollar against most major currencies in the third quarter of 2020. For the nine-month period ended October 2, 2020, currency
exchange rates negatively impacted reported sales by approximately 1.0% compared to the comparable period of 2019,
reflecting the strength of the U.S. dollar during the first six months of 2020 which more than offset the weakening experienced
in the third quarter of 2020. If the currency exchange rates in effect as of October 2, 2020 were to prevail throughout the
remainder of 2020, currency exchange rates would reduce the Company’s estimated full year 2020 sales by approximately 0.5%
on a year-over-year basis. Any future strengthening of the U.S. dollar against major currencies would adversely impact the
Company’s sales and results of operations for the remainder of the year, and any weakening of the U.S. dollar against major
currencies would positively impact the Company’s sales and results of operations for the remainder of the year.
Table of Contents
36

-- 39 of 73 --

UK’s Exit From the EU (“Brexit”)
The UK formally withdrew from the EU on January 31, 2020 with a transition period through December 31, 2020. During the
transition period, the UK continues to follow EU law and is negotiating with the EU on the terms of its relationship post-2020.
Failure to complete negotiations by the implementation deadline of December 31, 2020 could result in the UK reverting to
adverse trade agreements with the EU. The COVID-19 pandemic has created additional uncertainty regarding the likelihood
that the UK and the EU will complete negotiations by the December 31, 2020 deadline. As a result, the nature of the UK’s
future relationship with the EU is still uncertain. The Company continues to monitor the status of Brexit and plan for potential
impacts. To mitigate the potential impact of Brexit on the import of goods to the UK, the Company continues to strategically
manage its inventory levels and logistical channels with respect to the UK. The ultimate impact of Brexit on the Company’s
financial results is uncertain. For additional information, refer to the “Item 1A-Risk Factors” section of the Company’s 2019
Annual Report.
RESULTS OF OPERATIONS
Non-GAAP Measures
In this report, references to the non-GAAP measures of core sales (also referred to as core revenues or sales/revenues from
existing businesses) and core sales including Cytiva refer to sales from continuing operations calculated according to U.S.
GAAP, but excluding:
• sales from acquired businesses (as defined below, as applicable); and
• the impact of currency translation.
References to sales or operating profit attributable to acquisitions or acquired businesses refer to sales or operating profit, as
applicable, from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales and
operating profit, as applicable, attributable to divested product lines not considered discontinued operations; provided that in
calculating core sales including Cytiva, Cytiva’s sales (net of the sales of the Company product lines divested in 2020 to obtain
regulatory approval to acquire Cytiva, or the “divested product lines”) (“Cytiva sales”) are excluded from the definition of sales
attributable to acquisitions or acquired businesses. The portion of revenue attributable to currency translation is calculated as
the difference between:
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as applicable));
and
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as applicable))
after applying current period foreign exchange rates to the prior year period.
As noted above, beginning with results for the second quarter of 2020, the Company also presents core sales on a basis that
includes Cytiva sales. Historically Danaher has calculated core sales solely on a basis that excludes sales from acquired
businesses recorded prior to the first anniversary of the acquisition. However, given Cytiva’s significant size and historical core
sales growth rate, in each case compared to Danaher’s existing businesses, management believes it is appropriate to also present
core sales on a basis that includes Cytiva sales. Management believes this presentation provides useful information to investors
by demonstrating the impact Cytiva has on the Company’s current growth profile, rather than waiting to demonstrate such
impact 12 months after the acquisition when Cytiva would normally have been included in Danaher’s core sales calculation.
Danaher calculates period-to-period core sales growth including Cytiva by adding to the baseline period sales Cytiva’s
historical sales from such period (when it was owned by GE), net of the sales of the divested product lines, and also adding the
Cytiva sales to the current period.
Core sales growth (and the related measure of core sales including Cytiva) should be considered in addition to, and not as a
replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies.
Management believes that reporting these non-GAAP financial measures provides useful information to investors by helping
identify underlying growth trends in Danaher’s business and facilitating comparisons of Danaher’s revenue performance with
its performance in prior and future periods and to Danaher’s peers. Management also uses these non-GAAP financial measures
to measure the Company’s operating and financial performance and uses core sales growth as one of the performance measures
in the Company’s executive short-term cash incentive program. The Company excludes the effect of currency translation from
these measures because currency translation is not under management’s control, is subject to volatility and can obscure
underlying business trends, and excludes the effect of acquisitions (other than Cytiva sales, in the case of core growth including
Cytiva) and divestiture-related items because the nature, size, timing and number of acquisitions and divestitures can vary
Table of Contents
37

-- 40 of 73 --

dramatically from period-to-period and between the Company and its peers and can also obscure underlying business trends and
make comparisons of long-term performance difficult.
Throughout this discussion, references to sales volume refer to the impact of both price and unit sales and references to
productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing application of the Danaher
Business System.
Core Sales Growth and Core Sales Growth Including Cytiva
% Change Three-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
% Change Nine-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
Total sales growth (GAAP) 34.5 % 19.0 %
Impact of:
Acquisitions/divestitures (24.5) % (15.5) %
Currency exchange rates (1.0) % 1.0 %
Core sales growth (non-GAAP) 9.0 % 4.5 %
Impact of Cytiva sales growth (net of divested product lines) 5.0 % 3.0 %
Core sales growth including Cytiva (non-GAAP) 14.0 % 7.5 %
Operating Profit Performance
Operating profit margins increased 80 basis points from 17.7% during the three-month period ended September 27, 2019 to
18.5% for the three-month period ended October 2, 2020.
Third quarter 2020 vs. third quarter 2019 operating profit margin comparisons were favorably impacted by:
• Higher 2020 core sales volumes, lower overall spending levels for business travel and other business activities as a
result of the pandemic and incremental year-over-year cost savings associated with continuing productivity
improvement initiatives taken in 2020 and 2019, net of incremental year-over-year costs associated with various new
product development and sales, service and marketing growth investments - 310 basis points
• The incremental accretive effect in 2020 of acquired businesses, net of product line dispositions which did not qualify
as discontinued operations - 135 basis points
Third quarter 2020 vs. third quarter 2019 operating profit margin comparisons were unfavorably impacted by:
• Third quarter 2020 acquisition-related fair value adjustments to inventory and deferred revenue net of third quarter
2019 incremental transaction costs deemed significant, in each case related to the acquisition of Cytiva - 340 basis
points
• Impairment charges related to trade names in the Environmental & Applied Solutions segment incurred in the third
quarter of 2020 - 25 basis points
Operating profit margins decreased 80 basis points from 17.7% during the nine-month period ended September 27, 2019 to
16.9% for the nine-month period ended October 2, 2020.
Year-to-date 2020 vs. year-to-date 2019 operating profit margin comparisons were favorably impacted by:
• Higher 2020 core sales volumes, lower overall spending levels for business travel and other business activities as a
result of the pandemic and incremental year-over-year cost savings associated with continuing productivity
improvement initiatives taken in 2020 and 2019, net of incremental year-over-year costs associated with various new
product development and sales, service and marketing growth investments and the impact of foreign currency
exchange rates in the first nine months of 2020 - 85 basis points
• The incremental accretive effect in 2020 of acquired businesses, net of product line dispositions which did not qualify
as discontinued operations - 145 basis points
Table of Contents
38

-- 41 of 73 --

Year-to-date 2020 vs. year-to-date 2019 operating profit margin comparisons were unfavorably impacted by:
• First nine months of 2020 acquisition-related fair value adjustments to inventory and deferred revenue, and
incremental transaction costs deemed significant and integration preparation costs, in each case related to the
acquisition of Cytiva - 295 basis points
• Impairment charges related to trade names in the Environmental & Applied Solutions segment incurred in the third
quarter of 2020 - 10 basis points
• Impairment charges related to a facility in the Diagnostics segment and a trade name and other intangible assets in the
Environmental & Applied Solutions segment incurred in the first quarter of 2020 - 5 basis points
Business Segments
Sales by business segment for each of the periods indicated were as follows ($ in millions):
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Life Sciences $ 2,922.5 $ 1,695.6 $ 7,215.3 $ 5,035.1
Diagnostics 1,889.1 1,601.9 5,176.3 4,757.0
Environmental & Applied Solutions 1,071.6 1,080.5 3,132.1 3,250.6
Total $ 5,883.2 $ 4,378.0 $ 15,523.7 $ 13,042.7
For information regarding the Company’s sales by geographical region during the three and nine-month periods ended
October 2, 2020 and September 27, 2019, refer to Note 2 to the accompanying Consolidated Condensed Financial Statements.
LIFE SCIENCES
The Company’s Life Sciences segment offers a broad range of scientific tools that researchers use to study the basic building
blocks of life, including genes, proteins, cells, tissues and metabolites in order to understand the causes of disease, identify new
therapies and test new drugs and vaccines. The segment also offers the necessary tools and consumables to manufacture new
life saving drugs and is a leading provider of filtration, separation and purification technologies to the biopharmaceutical, food
and beverage, medical, aerospace, microelectronics and general industrial sectors.
Life Sciences Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 2,922.5 $ 1,695.6 $ 7,215.3 $ 5,035.1
Operating profit 504.9 342.5 1,242.9 995.5
Depreciation 51.0 31.7 132.4 96.8
Amortization of intangible assets 263.7 89.0 601.2 267.7
Operating profit as a % of sales 17.3 % 20.2 % 17.2 % 19.8 %
Depreciation as a % of sales 1.7 % 1.9 % 1.8 % 1.9 %
Amortization as a % of sales 9.0 % 5.2 % 8.3 % 5.3 %
Table of Contents
39

-- 42 of 73 --

Core Sales Growth and Core Sales Growth Including Cytiva
% Change Three-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
% Change Nine-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
Total sales growth (GAAP) 72.5 % 43.5 %
Impact of:
Acquisitions/divestitures (63.0) % (40.5) %
Currency exchange rates (1.0) % 0.5 %
Core sales growth (non-GAAP) 8.5 % 3.5 %
Impact of Cytiva sales growth (net of divested product lines) 10.0 % 7.0 %
Core sales growth including Cytiva (non-GAAP) 18.5 % 10.5 %
Price increases in the segment contributed 1.0% to sales growth on a year-over-year basis during both the three and nine-month
periods ended October 2, 2020 and are reflected as a component of core sales growth (or core sales growth including Cytiva, as
applicable).
In the first nine months of 2020, increased demand for instruments and consumables used in the bioprocessing end-market was
partially offset by lower demand related to non-COVID-19 applications as a result of the COVID-19 pandemic. The Company
saw lower demand for equipment late in the first quarter and in the second quarter as the COVID-19 pandemic spread around
the world, academic research labs closed late in the first quarter of 2020 and customers deferred purchases of larger
instruments. Later in the second quarter and continuing in the third quarter of 2020, the Company saw the gradual reopening of
certain research labs, led by China and followed by North America and Europe. Core sales for filtration, separation and
purification technologies increased across most major geographies for both the three and nine-month periods ended October 2,
2020 versus the comparable periods in 2019, led North America, Western Europe and China. Demand for filtration, separation
and purification technologies was led by the biopharmaceutical end-market, partially offset by weaker demand in the fluid
technology and asset protection and aerospace end-markets. Core sales of microscopy products declined during both the three
and nine-month periods across most major product lines, primarily due to lower demand in the medical and industrial end-
markets in both the three and nine-month periods and in the life science research end-market in the nine-month period.
Geographically, demand decreased in North America in both the three and nine-month periods and in Western Europe in the
nine-month period, as shutdown measures to curb COVID-19 reduced year-over-year demand for equipment in particular.
Demand for the Company’s flow cytometry and particle counting business increased across all major geographies in both the
three and nine-month periods. Core sales for the business’ flow cytometry solutions were driven by immune response testing
during the COVID-19 pandemic, while particle counting solutions grew due to increased biologic therapy development demand
and genomic sample preparation consumables and automation grew due to COVID-19 related increased molecular diagnostic
testing. Core sales in the mass spectrometry business increased during the three-month period, driven by demand for service
and demand in the capillary electrophoresis and pharmaceutical end-markets. Core sales in the mass spectrometry business
declined during the nine-month period, primarily due to lower demand in the clinical and pharmaceutical end-markets as a
result of the COVID-19 pandemic. Geographically, demand increased in the three-month period, led by North America and
China, and decreased in the nine-month period, primarily in China, Western Europe and North America. Core sales in the
genomics consumables business increased during both the three and nine-month periods across all major geographies, driven in
part by demand for primer and probe kits related to COVID-19 testing.
The acquisition of Cytiva on March 31, 2020 has provided, and is expected to continue to provide additional sales and earnings
growth opportunities for the Company’s Life Sciences segment by expanding the business’ geographic and product line
diversity, including new product and service offerings that complement the Company’s biologics workflow solutions. Due to
the proximity of the acquisition date to the end of the first quarter, there are no results of operations for Cytiva included in the
Life Sciences segment in the first quarter of 2020. Beginning in the second quarter of 2020, Cytiva is included in the Life
Sciences segment results. In the second and third quarter of 2020, Cytiva experienced increased demand across all major
geographies and all major end-markets, driven significantly by demand for instruments and consumables used in the research
and development of COVID-19-related treatments and vaccines.
Depreciation and amortization increased during both the three and nine-month periods ended October 2, 2020 as compared to
the comparable periods of 2019 due primarily to the impact of the acquisition of Cytiva.
Table of Contents
40

-- 43 of 73 --

Operating Profit Performance
Operating profit margins decreased 290 basis points during the three-month period ended October 2, 2020 as compared to the
comparable period of 2019.
Third quarter 2020 vs. third quarter 2019 operating profit margin comparisons were favorably impacted by:
• Higher 2020 core sales volumes, lower overall spending levels for business travel and other business activities as a
result of the pandemic, incremental year-over-year cost savings associated with the continuing productivity
improvement initiatives taken in 2020 and 2019 and the impact of foreign currency exchange rates in the third quarter
of 2020, net of incremental year-over-year costs associated with various sales, service and marketing growth
investments - 300 basis points
• The incremental accretive effect in 2020 of acquired businesses, net of product line dispositions which did not qualify
as discontinued operations - 200 basis points
Third quarter 2020 vs. third quarter 2019 operating profit margin comparisons were unfavorably impacted by:
• Third quarter 2020 acquisition-related fair value adjustments to inventory and deferred revenue related to the
acquisition of Cytiva - 790 basis points
Operating profit margins decreased 260 basis points during the nine-month period ended October 2, 2020 as compared to the
comparable period of 2019.
Year-to-date 2020 vs. year-to-date 2019 operating profit margin comparisons were favorably impacted by:
• Higher 2020 core sales volumes, lower overall spending levels for business travel and other business activities as a
result of the pandemic, incremental year-over-year cost savings associated with the continuing productivity
improvement initiatives taken in 2020 and 2019 and the impact of foreign currency exchange rates in the first nine
months of 2020, net of incremental year-over-year costs associated with various sales, service and marketing growth
investments - 145 basis points
• The incremental accretive effect in 2020 of acquired businesses, net of product line dispositions which did not qualify
as discontinued operations - 235 basis points
Year-to-date 2020 vs. year-to-date 2019 operating profit margin comparisons were unfavorably impacted by:
• First nine months of 2020 acquisition-related fair value adjustments to inventory and deferred revenue related to the
acquisition of Cytiva - 640 basis points
DIAGNOSTICS
The Company’s Diagnostics segment offers analytical instruments, reagents, consumables, software and services that hospitals,
physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Diagnostics Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 1,889.1 $ 1,601.9 $ 5,176.3 $ 4,757.0
Operating profit 408.0 266.0 952.4 782.0
Depreciation 95.7 94.3 290.6 280.1
Amortization of intangible assets 51.3 51.3 154.0 155.1
Operating profit as a % of sales 21.6 % 16.6 % 18.4 % 16.4 %
Depreciation as a % of sales 5.1 % 5.9 % 5.6 % 5.9 %
Amortization as a % of sales 2.7 % 3.2 % 3.0 % 3.3 %
Table of Contents
41

-- 44 of 73 --

Core Sales Growth
% Change Three-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
% Change Nine-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
Total sales growth (GAAP) 18.0 % 9.0 %
Impact of:
Currency exchange rates (0.5) % 1.0 %
Core sales growth (non-GAAP) 17.5 % 10.0 %
Pricing in the segment did not have a significant impact on sales growth on a year-over-year basis during either the three or
nine-month periods ended October 2, 2020.
In the first nine months of 2020, increased demand for molecular diagnostics and acute care instruments and consumables to
support the response to the COVID-19 pandemic was partially offset by lower demand for instruments and consumables in the
clinical lab and pathology businesses as a result of shutdowns and restrictions related to the pandemic. While patient volumes
remained down year-over-year, in the third quarter of 2020, the Company has seen sequential improvement in patient volume
from the second quarter to the third quarter of 2020. Core sales in the segment’s clinical lab business decreased on a year-over-
year basis for both the three and nine-month periods ended October 2, 2020, driven by lower demand across all major product
lines. Geographically, shutdown measures to curb COVID-19 reduced core laboratory testing volumes year-over-year across
all major geographies in both periods. During both the three and nine-month periods, core sales increased in the molecular
diagnostics business on a year-over-year basis in both developed and high-growth markets, which contributed significantly to
overall segment core sales growth. The business experienced particularly strong growth in sales of instruments and
consumables in the infectious disease product line in both the three and nine-month periods ended October 2, 2020, driven by
the development and commercialization of diagnostic test solutions for COVID-19. Core sales in the acute care diagnostic
business increased year-over-year in both the three and nine-month periods driven in part by increased hospitalizations as a
result of the COVID-19 pandemic, led by demand for blood gas instruments in both periods as well as demand for consumables
in the nine-month period. Geographically, demand was strong across all major geographies. Core sales in the pathology
business grew year-over-year in the three-month period ended October 2, 2020, due to increased demand for advanced staining
consumables and pathology imaging products. During the nine-month period, core sales in the pathology business declined
year-over-year due to lower demand during the first six months of 2020 as a result of the COVID-19 pandemic.
Geographically, core sales increased in the three-month period, led by North America, Western Europe and China, while in the
nine-month period core sales decreased as lower demand in China, North America and other developed markets more than
offset increased demand in Western Europe and high-growth markets (other than China).
Operating Profit Performance
Operating profit margins increased 500 basis points during the three-month period ended October 2, 2020 as compared to the
comparable period of 2019. Year-over-year operating profit margin comparisons were favorably impacted by higher 2020 core
sales volumes, lower overall spending levels for business travel and other business activities as a result of the pandemic and
incremental year-over-year cost savings associated with the continuing productivity improvement initiatives taken in 2020 and
2019, net of incremental year-over-year costs associated with various new product development, sales, service and marketing
growth investments and the impact of foreign currency exchange rates in the third quarter of 2020.
Operating profit margins increased 200 basis points during the nine-month period ended October 2, 2020 as compared to the
comparable period of 2019.
Year-to-date 2020 vs. year-to-date 2019 operating profit margin comparisons were favorably impacted by:
• Higher 2020 core sales volumes, lower overall spending levels for business travel and other business activities as a
result of the pandemic and incremental year-over-year cost savings associated with the continuing productivity
improvement initiatives taken in 2020 and 2019, net of incremental year-over-year costs associated with various new
product development, sales, service and marketing growth investments, unfavorable product mix and the impact of
foreign currency exchange rates in the first nine months of 2020 - 210 basis points
Year-to-date 2020 vs. year-to-date 2019 operating profit margin comparisons were unfavorably impacted by:
• Impairment charges related to a facility incurred in the first quarter of 2020 - 10 basis points
Table of Contents
42

-- 45 of 73 --

Depreciation and amortization both decreased as a percentage of sales during both the three and nine-month periods ended
October 2, 2020, primarily as a result of the increase in sales in both periods.
ENVIRONMENTAL & APPLIED SOLUTIONS
The Company’s Environmental & Applied Solutions segment offers products and services that help protect important resources
and keep global food and water supplies safe. The Company’s water quality business provides instrumentation, consumables,
software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial,
waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. The
Company’s product identification business provides equipment, software, services and consumables for various color and
appearance management, packaging design and quality management, packaging converting, printing, marking, coding and
traceability applications on consumer, pharmaceutical and industrial products.
Environmental & Applied Solutions Selected Financial Data
Three-Month Period Ended Nine-Month Period Ended
($ in millions) October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 1,071.6 $ 1,080.5 $ 3,132.1 $ 3,250.6
Operating profit 245.1 256.5 707.0 761.3
Depreciation 11.3 11.6 34.6 36.6
Amortization of intangible assets 16.1 15.3 46.4 46.5
Operating profit as a % of sales 22.9 % 23.7 % 22.6 % 23.4 %
Depreciation as a % of sales 1.1 % 1.1 % 1.1 % 1.1 %
Amortization as a % of sales 1.5 % 1.4 % 1.5 % 1.4 %
Core Sales Growth
% Change Three-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
% Change Nine-
Month Period Ended
October 2, 2020 vs.
Comparable 2019
Period
Total sales decline (GAAP) (1.0) % (3.5) %
Impact of:
Currency exchange rates — % 1.0 %
Core sales decline (non-GAAP) (1.0) % (2.5) %
Price increases in the segment contributed 2.0% and 1.5% to sales growth on a year-over-year basis during the three and nine-
month periods ended October 2, 2020, respectively, and are reflected as a component of core revenue growth (decline).
Core sales in the segment’s water quality business decreased at a low-single digit rate during the three-month period ended
October 2, 2020 compared to the comparable period of 2019 primarily as a result of lower demand year-over-year for
equipment as a result of the COVID-19 pandemic. While demand for equipment decreased on a year-over-year basis in the
third quarter of 2020, the Company saw sequential improvement in the demand for equipment from the second quarter to the
third quarter of 2020. On an overall basis, core sales in the water quality business were essentially flat during the nine-month
period ended October 2, 2020 compared to the comparable period of 2019 as strong demand for consumables in the first quarter
was offset by weakness experienced in the second and third quarters of 2020. Year-over-year core sales in the analytical
instrumentation product line decreased in the three-month period, as decreases in Western Europe and the Middle East more
than offset increases in North America and China. In the nine-month period, core sales decreased as lower core sales in North
America and the Middle East more than offset increased core sales in Western Europe and China. Core sales in the business’
chemical treatment solutions product line decreased during the three-month period and increased during the nine-month period.
Core sales were negatively impacted in both periods by lower demand in the oil and gas, primary metals, transportation and
mining end-markets, partially offset in the nine-month period by increased demand in the food and beverage, consumer and
industrial, and power end-markets. Geographically, year-over-year core sales for chemical treatment solutions increased in
North America and decreased in the high-growth markets, led by Latin America, during both the three and nine-month periods.
Core sales in the business’ ultraviolet water disinfection product line increased during both the three and nine-month periods, as
increased demand in North America offset weaker demand in the high-growth markets.
Table of Contents
43

-- 46 of 73 --

Core sales in the segment’s product identification businesses decreased at a low-single digit rate during the three-month period
and at a mid-single digit rate during the nine-month period ended October 2, 2020 compared to the comparable periods of 2019
driven by lower demand for equipment as a result of the COVID-19 pandemic. While demand for equipment decreased on a
year-over-year basis in the third quarter of 2020, the Company saw sequential improvement in the demand for equipment from
the second quarter to the third quarter of 2020. Core sales in the marking and coding business increased during the three-month
period driven by increased demand in North America and the high-growth markets partially offset by lower demand in Western
Europe. During the nine-month period, core sales decreased as weaker demand in Western Europe and the high-growth
markets more than offset increased demand in North America. In both periods, demand for marking and coding equipment
decreased, offset by growth in consumables in the food and beverage, consumer-packaged goods and pharmaceutical end-
markets. For packaging and color solutions products and services, core sales decreased in both the three and nine-month
periods, driven by lower demand for equipment in Western Europe, North America and the high-growth markets.
Operating Profit Performance
Operating profit margins decreased 80 basis points during the three-month period ended October 2, 2020 as compared to the
comparable period of 2019.
Third quarter 2020 vs. third quarter 2019 operating profit margin comparisons were favorably impacted by:
• Lower overall spending levels for business travel and other business activities as a result of the pandemic, incremental
year-over-year cost savings associated with continuing productivity improvement initiatives taken in 2020 and 2019
and the impact of foreign currency exchange rates in the third quarter of 2020, net of lower 2020 core sales volumes
and incremental year-over-year costs associated with sales, service and marketing growth investments - 75 basis points
Third quarter 2020 vs. third quarter 2019 operating profit margin comparisons were unfavorably impacted by:
• Impairment charges related to trade names incurred in the third quarter of 2020 - 130 basis points
• The incremental net dilutive effect in 2020 of acquired businesses - 25 basis points
Operating profit margins decreased 80 basis points during the nine-month period ended October 2, 2020 as compared to the
comparable period of 2019. Year-over-year operating profit margin comparisons were unfavorably impacted by:
• Lower 2020 core sales volumes, incremental year-over-year costs associated with sales, service and marketing growth
investments, net of lower overall spending levels for business travel and other business activities as a result of the
pandemic, incremental year-over-year cost savings associated with continuing productivity improvement initiatives
taken in 2020 and 2019 and the impact of foreign currency exchange rates in the first nine months of 2020 - 20 basis
points
• Impairment charges related to trade names incurred in the third quarter of 2020 - 45 basis points
• Impairment charges related to a trade name and other intangible assets incurred in the first quarter of 2020 - 10 basis
points
• The incremental net dilutive effect in 2020 of acquired businesses - 5 basis points
COST OF SALES AND GROSS PROFIT
Three-Month Period Ended Nine-Month Period Ended
($ in millions) October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 5,883.2 $ 4,378.0 $ 15,523.7 $ 13,042.7
Cost of sales (2,657.7) (1,936.6) (7,002.8) (5,762.6)
Gross profit $ 3,225.5 $ 2,441.4 $ 8,520.9 $ 7,280.1
Gross profit margin 54.8 % 55.8 % 54.9 % 55.8 %
The year-over-year increase in cost of sales during both the three and nine-month periods ended October 2, 2020 as compared
to the comparable periods in 2019, was due primarily to the impact of higher year-over-year sales volumes, including sales
volumes from recently acquired businesses, and 2020 acquisition-related charges associated with fair value adjustments to
inventory in connection with the Cytiva Acquisition, which increased cost of sales by $220 million and $417 million during the
three and nine-month periods ended October 2, 2020, respectively.
Table of Contents
44

-- 47 of 73 --

The year-over-year decrease in gross profit margins during both the three and nine-month periods ended October 2, 2020 as
compared to the comparable periods in 2019, was primarily due to 2020 acquisition-related charges associated with fair value
adjustments to inventory and deferred revenue in connection with the Cytiva Acquisition, which adversely impacted gross
profit margin comparisons by approximately 380 basis points and 280 basis points during the three and nine-month periods
ended October 2, 2020, respectively. The impact of higher year-over-year sales volumes, including sales volumes from
recently acquired businesses, and higher gross profit margins of recently acquired businesses partially offset this negative
factor.
OPERATING EXPENSES
Three-Month Period Ended Nine-Month Period Ended
($ in millions) October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Sales $ 5,883.2 $ 4,378.0 $ 15,523.7 $ 13,042.7
Selling, general and administrative (“SG&A”)
expenses 1,795.3 1,382.5 4,939.0 4,140.2
Research and development (“R&D”) expenses 342.6 282.6 952.2 832.2
SG&A as a % of sales 30.5 % 31.6 % 31.8 % 31.7 %
R&D as a % of sales 5.8 % 6.5 % 6.1 % 6.4 %
The year-over-year decrease in SG&A expenses as a percentage of sales for the three-month period ended October 2, 2020 as
compared to the comparable period in 2019, was driven by the benefit of increased leverage of the Company’s general and
administrative cost base resulting from higher 2020 sales volumes, including sales volumes from recently acquired companies,
incremental year-over-year cost savings associated with the continuing productivity improvement initiatives taken in 2020 and
2019, lower travel expenses in 2020 and lower year-over-year transaction costs related to the Cytiva Acquisition. These
decreases were partially offset by incremental year-over-year amortization charges, primarily related to the Cytiva Acquisition,
which adversely impacted SG&A as a percentage of sales by approximately 205 basis points, impairment charges related to
trade names in the Environmental & Applied solutions segment incurred in the third quarter of 2020 and continued investments
in sales and marketing growth initiatives. The year-over-year increase in SG&A expenses as a percentage of sales for the nine-
month period ended October 2, 2020 as compared to the comparable period in 2019, was driven by incremental year-over-year
amortization charges, primarily related to the Cytiva Acquisition, which adversely impacted SG&A as a percentage of sales by
approximately 155 basis points, impairment charges related to a facility in the Diagnostics segment and trade name and other
intangible assets in the Environmental & Applied solutions segment incurred in the first and third quarters of 2020 and
continued investments in sales and marketing growth initiatives. These decreases were partially offset by the benefit of
increased leverage of the Company’s general and administrative cost base resulting from higher 2020 sales volumes, including
sales volumes from recently acquired companies, incremental year-over-year cost savings associated with the continuing
productivity improvement initiatives taken in 2020 and 2019, lower travel expenses in 2020 and lower year-over-year
transaction costs related to the Cytiva Acquisition.
R&D expenses (consisting principally of internal and contract engineering personnel costs) as a percentage of sales declined
during both the three and nine-month periods ended October 2, 2020 as compared to the comparable periods of 2019. The
decline was primarily due to lower R&D expenses as a percentage of sales in businesses recently acquired as well as the impact
of sales growth rates exceeding the spending growth related to the Company's new product development initiatives.
OTHER (EXPENSE) INCOME, NET
The Company disaggregates the service cost component of net periodic benefit costs of the noncontributory defined benefit
pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in
other (expense) income, net. These other components include the assumed rate of return on plan assets, partially offset by
amortization of actuarial losses and interest and aggregated to a gain of $3 million and $14 million for the three and nine-month
periods ended October 2, 2020, respectively, compared to a gain of $4 million and $14 million for the three and nine-month
periods ended September 27, 2019.
The Company estimates the fair value of investments in equity securities using the Fair Value Alternative and records
adjustments to fair value within net earnings. Additionally, the Company is a limited partner in a partnership that invests in
early stage companies. While the partnership records these investments at fair value, the Company’s investment in the
partnership is accounted for under the equity method of accounting. During the three and nine-month periods ended October 2,
2020, the Company recorded unrealized gains of $3 million and unrealized losses of $10 million, respectively, related to
changes in the fair value of these investments. No significant realized or unrealized gains or losses were recorded in the three
Table of Contents
45

-- 48 of 73 --

and nine-month periods ended September 27, 2019 with respect to these investments.
GAIN ON SALE OF PRODUCT LINES
As a condition to obtaining certain regulatory approvals for the closing of the Cytiva Acquisition, the Company was required to
divest certain of its existing product lines in the Life Sciences segment that in the aggregate generated revenues of
approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of these product lines for a cash
purchase price, net of cash transferred and transaction costs, of $826 million and recognized a pretax gain on sale of $455
million ($305 million after-tax or $0.42 per diluted common share) in the second quarter of 2020. The divestiture of these
product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and
therefore is not reported as a discontinued operation.
INTEREST COSTS AND FINANCING
For a discussion of the Company’s outstanding indebtedness, refer to Note 7 to the accompanying Consolidated Condensed
Financial Statements.
Interest expense of $77 million and $203 million for the three and nine-month periods ended October 2, 2020, respectively, was
$53 million higher and $139 million higher than the comparable periods of 2019, due primarily to the higher average debt
balances as a result of the issuances of debt in September 2019, November 2019, March 2020 and April 2020, higher U.S.-
dollar denominated commercial paper borrowings in 2020, compared to the comparable periods of 2019, and 2020 borrowings
under the Five-Year Facility and the Superseded 364-Day Facility.
Interest income of $4 million and $68 million for the three and nine-month periods ended October 2, 2020, respectively, was
$26 million lower and $4 million lower than the comparable periods of 2019, due primarily to lower rates on cash deposits,
partially offset in the nine-month period by higher average cash balances during the first quarter of 2020 attributable to the cash
raised to fund the Cytiva Acquisition.
INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended Nine-Month Period Ended
October 2, 2020 September 27, 2019 October 2, 2020 September 27, 2019
Effective tax rate 13.5 % 19.8 % 18.5 % 29.6 %
The effective tax rate for the three-month period ended October 2, 2020 differs from the U.S. federal statutory rate of 21.0%
principally due to the release of reserves for uncertain tax positions from audit settlements and expiration of statutes of
limitation, excess tax benefits from stock-based compensation, and other items. These items decreased the reported tax rate by
6.1%.
The effective tax rate for the nine-month period ended October 2, 2020 differs from the U.S. federal statutory rate of 21.0%
principally due to release of reserves for uncertain tax positions from audit settlements and expiration of statutes of limitation,
and excess tax benefits from stock-based compensation, partially offset by a higher tax rate associated with the gain on the
divestiture of certain product lines in the Life Sciences segment and changes in estimates associated with prior period uncertain
tax positions. These items decreased the reported tax rate on a net basis by 1.1%.
The effective tax rate for the three-month period ended September 27, 2019 differs from the U.S. federal statutory rate of 21.0%
principally due to the impact of earnings outside the United States which generally are taxed at rates lower than the U.S. federal
rate.
The effective tax rate for the nine-month period ended September 27, 2019 differs from the U.S. federal statutory rate of 21.0%
principally due to the impact of net discrete charges of $227 million ($0.31 per diluted common share) related primarily to
changes in estimates associated with prior period uncertain tax positions and audit settlements, net of the release of reserves for
uncertain tax positions due to the expiration of statutes of limitation, release of valuation allowances associated with certain
foreign tax credits, tax benefits resulting from changes in tax law and excess tax benefits from stock-based compensation.
These net discrete income tax charges increased the reported tax rate by 9.7%.
The Company conducts business globally, and files numerous consolidated and separate income tax returns in federal, state and
foreign jurisdictions. In addition to the Company’s significant presence in the U.S., the Company also has a significant
presence in China, Denmark, Germany, Singapore, Sweden, Switzerland and the UK. Excluding these jurisdictions, the
Table of Contents
46

-- 49 of 73 --

Company believes that a change in the statutory tax rate of any individual foreign country would not have a material impact on
the on-going effective tax rate of the Company given the geographical dispersion of the Company’s taxable income.
The Company and its subsidiaries are routinely examined by various domestic and international taxing authorities. The Internal
Revenue Service (“IRS”) has completed the examinations of substantially all of the Company’s federal income tax returns
through 2015 and is currently examining certain of the Company’s federal income tax returns for 2016 through 2018. In
addition, the Company has subsidiaries in Austria, Belgium, Canada, China, Denmark, France, Germany, India, Japan, Korea,
Switzerland, the UK and various other countries, states and provinces that are currently under audit for years ranging from 2004
through 2018.
In the fourth quarter of 2018 and in the first quarter of 2019, the IRS proposed significant adjustments to the Company’s taxable
income for the years 2012 through 2015 with respect to the deferral of tax on certain premium income related to the Company’s
self-insurance programs. For income tax purposes, the recognition of premium income has been deferred in accordance with
U.S. tax laws related to insurance. The IRS challenged the deferral of premiums for certain types of the Company’s self-
insurance policies. These proposed adjustments would have increased the Company’s taxable income over the 2012 through
2015 period by approximately $2.7 billion. In the third quarter of 2020, the Company settled the 2012 through 2015 audit
period with the IRS, including the resolution of these proposed adjustments. The settlement was not material to the Company’s
financial statements, including its cash flows and effective tax rate. As the settlement with the IRS was specific to the audit
period, the settlement does not preclude the IRS from proposing similar adjustments to the Company’s self-insurance programs
in current or future audits. In connection with its examination of the Company’s federal income tax returns for 2016, 2017 and
2018, the IRS has requested additional information on the Company’s self-insurance programs. Due to the enactment of the
Tax Cuts and Jobs Act in 2017 and the resulting reduction in the U.S. corporate tax rate for years after 2017, the Company
revalued its deferred tax liabilities related to the temporary differences associated with this deferred premium income from
35.0% to 21.0%. If the IRS proposes adjustments related to the Company’s self-insurance premiums with respect to years
subsequent to 2015 and the Company is unsuccessful in defending its position, any taxes owed to the IRS may be computed
under the previous 35.0% statutory tax rate and the Company may be required to revalue the related deferred tax liabilities from
21.0% to 35.0%, which in addition to any interest due on the amounts assessed, would require a charge to future earnings.
Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws.
Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries.
On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) of approximately DKK
1.9 billion including interest (approximately $292 million based on the exchange rate as of October 2, 2020), imposing
withholding tax relating to interest accrued in Denmark on borrowings by certain of the Company’s subsidiaries for the years
2004-2009. The Company appealed these assessments to the Danish National Tax Tribunal in 2014. The appeal is pending,
awaiting the final outcome of other, preceding withholding tax cases that were appealed to the Danish Courts and subsequently
to the Court of Justice of the European Union (“CJEU”). In February 2019, the CJEU decided several of these cases and ruled
that the exemption of interest payments from withholding taxes provided in the applicable EU directive should be denied where
taxpayers use the directive for abusive or fraudulent purposes, and that it is up to the national courts to make this determination.
This decision of the CJEU now awaits application by the Danish High Court in the other, preceding withholding tax cases.
SKAT has maintained a similar position related to withholding tax on interest accrued in Denmark on borrowings by certain of
the Company’s subsidiaries with respect to tax years 2010-2012 and 2013-2015. On August 27, 2019 and December 16, 2019,
the Company received assessments for these matters of approximately DKK 1.1 billion including interest (approximately $169
million based on the exchange rate as of October 2, 2020) for tax years 2010-2012 and DKK 761 million including interest
(approximately $120 million based on the exchange rate as of October 2, 2020) for tax years 2013-2015, respectively. The
Company is appealing these assessments as well.
Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is
vigorously defending its positions. The Company intends on pursuing this matter through the Danish High Court should the
appeal to the Danish National Tax Tribunal be unsuccessful. The Company will continue to monitor decisions of both the
Danish courts and the CJEU and evaluate the impact of these court rulings on the Company’s tax positions in Denmark. The
ultimate resolution of this matter is uncertain, could take many years, and could result in a material adverse impact to the
Company’s financial statements, including its cash flow and effective tax rate.
On June 24, 2020, SKAT issued a press release to announce that it has misapplied Denmark’s interest rules in some
assessments concerning withholding tax. The Company’s subsidiaries in Denmark have been notified that they may be one of
the companies potentially overcharged interest but a determination of the impact of such notice has not been received.
The Company expects its effective tax rate for the remainder of 2020 to be approximately 19.6%. The Company’s effective tax
rate could vary as a result of many factors, including but not limited to the following:
Table of Contents
47

-- 50 of 73 --

• The expected rate for the remainder of 2020 includes the anticipated discrete income tax benefits from excess tax
deductions related to the Company’s stock compensation programs, which are reflected as a reduction in tax expense,
though the actual benefits (if any) will depend on the Company’s stock price and stock option exercise patterns.
• The actual mix of earnings by jurisdiction could fluctuate from the Company’s projection, particularly given the
uncertainties related to the COVID-19 pandemic.
• The tax effects of other discrete items, including accruals related to tax contingencies, the resolution of worldwide tax
matters, tax audit settlements, statute of limitations expirations and changes in tax regulations.
• Any future legislative changes or potential tax reform, the impact of future regulations and guidance implementing the
Tax Cuts and Jobs Act and any related additional tax planning efforts to address these changes.
As a result of the uncertainty in predicting these items, it is reasonably possible that the actual effective tax rate used for
financial reporting purposes will change in future periods.
COMPREHENSIVE INCOME
For the three and nine-month periods ended October 2, 2020, comprehensive income attributable to Danaher increased
approximately $1.3 billion and approximately $3.0 billion, respectively, as compared to the comparable periods of 2019,
primarily driven by gains from foreign currency translation adjustments and higher net earnings in both the three and nine-
month periods and gains from cash flow hedge adjustments in the nine-month period. The Company recorded foreign currency
translation gains of $923 million and approximately $1.8 billion for the three and nine-month periods ended October 2, 2020,
respectively, as compared to foreign currency translation losses of $236 million and $293 million for the three and nine-month
periods ended September 27, 2019, respectively. The Company recorded a loss of $90 million and a gain of $176 million from
cash flow hedge adjustments related to the Company’s cross-currency swap derivative contracts for the three and nine-month
periods ended October 2, 2020, respectively, as compared to losses of $42 million and $49 million for the three and nine-month
periods ended September 27, 2019, respectively.
INFLATION
The effect of inflation on the Company’s revenues and net earnings was not significant in the three and nine-month periods
ended October 2, 2020.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing and
financing activities.
The Company continues to generate substantial cash from operating activities and believes that its operating cash flows, cash on
hand and other available sources of liquidity will be sufficient to allow it to continue investing in existing businesses,
consummating strategic acquisitions and investments, paying interest and servicing debt, funding restructuring activities and
managing its capital structure on a short-term and long-term basis.
Notwithstanding the foregoing, the Company continues to monitor the impact of the COVID-19 pandemic on the Company’s
liquidity and capital resources and take actions intended to mitigate adverse impacts. Historically, the Company has generally
relied on borrowings under its commercial paper program to address liquidity requirements that exceed the capacity provided
by its operating cash flows and cash on hand, while also accessing the capital markets from time to time to secure financing for
more significant acquisitions. The COVID-19 pandemic adversely affected the availability of new borrowings in the
commercial paper markets in the late first quarter and in the second quarter of 2020. Therefore, in March and April 2020, the
Company borrowed $2.5 billion under the Five-Year Facility and $2.5 billion under the Superseded 364-Day Facility for
general corporate purposes (including payment of a portion of the purchase price for the Cytiva Acquisition and repayment of
certain commercial paper obligations as they mature), and also issued approximately €2.5 billion (approximately $2.7 billion
based on currency exchange rates as of the respective dates of the pricing of the notes) aggregate principal amount of euro-
denominated long-term debt, the proceeds of which have been and are being used for general corporate purposes (including
repayment of the borrowings under the Superseded 364-Day Facility and the Five-Year Facility, and repayment of certain
commercial paper obligations as they mature). Additionally, in May 2020, the Company completed the 2020 Common Stock
Offering and 2020 MCPS Offering and received net proceeds of approximately $1.73 billion and $1.67 billion, respectively.
On June 5, 2020, the Company entered into a new $2.5 billion 364-Day Facility with a syndicate of banks that expires on June
4, 2021 to replace the Superseded 364-Day Facility. As of October 2, 2020, after taking into account amounts backstopping
Table of Contents
48

-- 51 of 73 --

outstanding commercial paper, the Company had availability under its Credit Facilities of approximately $5.6 billion for direct
borrowings or to backstop the issuance of additional commercial paper to the extent available.
Following is an overview of the Company’s cash flows and liquidity ($ in millions):
Overview of Cash Flows and Liquidity
Nine-Month Period Ended
($ in millions) October 2, 2020 September 27, 2019
Total operating cash provided by continuing operations $ 3,993.7 $ 2,661.7
Cash paid for acquisitions $ (20,818.5) $ (331.1)
Payments for additions to property, plant and equipment (475.2) (456.5)
Proceeds from sales of property, plant and equipment 1.4 12.5
Payments for purchases of investments (214.9) (163.4)
Proceeds from sale of product lines 825.9 —
All other investing activities 23.6 29.1
Total investing cash used in continuing operations $ (20,657.7) $ (909.4)
Proceeds from the issuance of common stock in connection with stock-based
compensation $ 125.2 $ 115.0
Proceeds from the sale of common stock, net of issuance costs 1,728.5 1,443.2
Proceeds from the sale of preferred stock, net of issuance costs 1,668.1 1,599.6
Proceeds from the sale of Envista Holdings Corporation common stock, net of
issuance costs — 643.4
Payment of dividends (445.4) (385.0)
Net (repayments of) proceeds from borrowings (maturities of 90 days or less) (3,339.3) 744.1
Net proceeds from borrowings (maturities longer than 90 days) 7,691.3 8,137.1
Net repayments of borrowings (maturities longer than 90 days) (5,000.0) (680.9)
All other financing activities (2.7) (6.0)
Net operating cash provided by financing activities $ 2,425.7 $ 11,610.5
• Operating cash flows from continuing operations increased approximately $1.3 billion, or approximately 50%, during
the nine-month period ended October 2, 2020 as compared to the comparable period of 2019, due to higher net
earnings (after excluding noncash impairment charges and fair value adjustments related to certain long-lived assets in
2020, noncash charges for depreciation, amortization and stock compensation in both periods, and noncash discrete tax
charges in 2019), higher cash provided by trade accounts receivables, prepaid expenses and other assets, and accrued
expenses and other liabilities during the 2020 period compared to the prior year, partially offset by higher cash used
for inventories and trade accounts payable in 2020 compared to the prior year.
• Net cash used in investing activities consisted primarily of cash paid for acquisitions. The Company acquired Cytiva
during the nine-month period ended October 2, 2020 for total cash consideration of approximately $20.7 billion (net of
approximately $0.1 billion of acquired cash). In addition to Cytiva, the Company acquired one other business for $104
million during the nine-month period ended October 2, 2020. Refer to Note 3 to the accompanying Consolidated
Condensed Financial Statements for additional information on the Company’s acquisitions.
• On March 24, 2020, the Company borrowed $2.5 billion under the Five-Year Facility and on April 7, 2020, the
Company borrowed $2.5 billion under the Superseded 364-Day Facility. The Company repaid $1.25 billion of the
borrowings under the Five-Year Facility and all of the borrowings under the Superseded 364-Day Facility in May
2020. The Company repaid the remaining $1.25 billion of the borrowings under the Five-Year Facility in September
2020. On March 30, 2020 and April 8, 2020, the Company issued senior unsecured Euronotes and received net
proceeds of approximately €1.7 billion (approximately $1.9 billion based on currency exchange rates as of the date of
the pricing of the notes) and approximately €754 million (approximately $816 million based on currency exchange
rates as of the date of the pricing of the notes), respectively.
Table of Contents
49

-- 52 of 73 --

• In May 2020, the Company completed the 2020 Common Stock Offering and the 2020 MCPS offering, resulting in net
proceeds of approximately $1.73 billion, after deducting expenses and the underwriters’ discount of $54 million, and
approximately $1.67 billion, after deducting expenses and the underwriters’ discount of $49 million, respectively.
• As of October 2, 2020, the Company held approximately $5.7 billion of cash and cash equivalents.
Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the timing
of payments for income taxes, restructuring activities, pension funding and other items impact reported cash flows.
Operating cash flows from continuing operations were approximately $4.0 billion for the first nine months of 2020, an increase
of approximately $1.3 billion, or approximately 50%, as compared to the comparable period of 2019. The year-over-year
change in operating cash flows from 2019 to 2020 was primarily attributable to the following factors:
• 2020 operating cash flows reflected an increase of $767 million in net earnings from continuing operations for the first
nine months of 2020 as compared to the comparable period in 2019. Partially offsetting the impact of this increase is
the fact that 2019 net earnings from continuing operations include $227 million of net discrete noncash tax charges
compared to a net discrete noncash tax benefit of $85 million in 2020. In addition, net earnings from continuing
operations in 2020 included $32 million in aggregate of noncash impairment charges and fair value adjustments related
to certain long-lived assets. Each of these noncash charges and adjustments decreased earnings without a
corresponding impact to operating cash flows.
• Net earnings for the first nine months of 2020 also reflected an increase of $813 million of depreciation, amortization
(intangible assets and inventory step-up) and stock compensation expense as compared to the comparable period of
2019. Amortization expense primarily relates to the amortization of intangible assets and inventory fair value
adjustments. Depreciation expense relates to both the Company’s manufacturing and operating facilities as well as
instrumentation leased to customers under OTL arrangements. Depreciation, amortization and stock compensation are
noncash expenses that decrease earnings without a corresponding impact to operating cash flows.
• The aggregate of trade accounts receivable, inventories and trade accounts payable used $139 million in operating cash
flows during the first nine months of 2020, compared to $236 million of operating cash flows used in the comparable
period of 2019. The amount of cash flow generated from or used by the aggregate of trade accounts receivable,
inventories and trade accounts payable depends upon how effectively the Company manages the cash conversion
cycle, which effectively represents the number of days that elapse from the day it pays for the purchase of raw
materials and components to the collection of cash from its customers and can be significantly impacted by the timing
of collections and payments in a period.
• The aggregate of prepaid expenses and other assets and accrued expenses and other liabilities provided $361 million of
operating cash flows during the first nine months of 2020, compared to $251 million of operating cash flows provided
in the comparable period of 2019. The noncash discrete tax items noted above, the timing of cash payments for
transaction costs incurred in connection with the Cytiva Acquisition and various employee-related liabilities, partially
offset by cash payments for income taxes, customer funding and changes in accrued expenses, drove the majority of
this change.
The continuing impact of the COVID-19 pandemic may have an adverse impact on the Company’s operating cash flow if the
measures to contain and mitigate the spread of COVID-19 adversely impact the Company’s sales and earnings, the collections
of accounts receivable, including delays in collections and increases in uncollectible receivables, and/or adversely impact our
supply chain and inventory levels. The future impact from the COVID-19 pandemic on the Company’s operating cash flow is
highly uncertain but may be material.
Investing Activities
Cash flows relating to investing activities consist of cash used for acquisitions and capital expenditures, including instruments
leased to customers, cash used for investments and cash proceeds from divestitures of businesses or assets.
Net cash used in investing activities increased approximately $19.7 billion in the nine-month period ended October 2, 2020
compared to the comparable period of 2019, primarily as a result of the Company’s acquisition of Cytiva in the first quarter of
2020. For a discussion of the Company’s acquisitions and divestitures during the first nine months of 2020 refer to “—
Overview”.
Table of Contents
50

-- 53 of 73 --

Capital expenditures are made primarily for increasing capacity, replacing equipment, supporting new product development,
improving information technology systems and the manufacture of instruments that are used in OTL arrangements that certain
of the Company’s businesses enter into with customers. Capital expenditures increased $19 million on a year-over-year basis
for the nine-month period ended October 2, 2020 compared to the comparable period in 2019, due to capital expenditures to
support production of products related to testing, treatment and vaccines for COVID-19 and capital expenditures at Cytiva,
partially offset by declines in expenditures for instruments used in OTL arrangements. For the full year 2020, the Company
forecasts capital spending to be approximately $800 million, though actual expenditures will ultimately depend on business
conditions. The Company anticipates declines in expenditures for instruments used in OTL arrangements due to the COVID-19
pandemic to be offset by increased capital expenditures to support production of products related to COVID-19 and increases in
capital expenditures as a result of the Cytiva Acquisition.
Financing Activities and Indebtedness
Cash flows relating to financing activities typically consist primarily of cash flows associated with the issuance and repayments
of commercial paper, issuance and repayment of notes payable and long-term debt, borrowings under committed credit
facilities, issuance and repurchases of common stock, issuance of preferred stock and payments of cash dividends to
shareholders. Financing activities provided cash of approximately $2.4 billion during the nine-month period ended October 2,
2020 compared to approximately $11.6 billion of cash provided in the comparable period of 2019. The year-over-year decrease
in cash provided by financing activities was due primarily to the significant borrowings incurred in 2019 to finance the Cytiva
Acquisition, partially offset by borrowings incurred in 2020 to finance the remaining amounts needed to acquire Cytiva and for
general corporate purposes.
For a description of the Company’s financing activities in the nine months of 2020, the Company’s outstanding debt as of
October 2, 2020 and the Company’s commercial paper programs and credit facilities, refer to Note 7 to the accompanying
Consolidated Condensed Financial Statements. As of October 2, 2020, the Company was in compliance with all of its
respective debt covenants. Credit support for the Company’s commercial paper program is provided by the Five-Year Facility
and the 364-Day Facility.
For a description of the Company’s financing of the Cytiva Acquisition, refer to Note 3 to the accompanying Consolidated
Condensed Financial Statements.
See Notes 7 and 16 to the accompanying Consolidated Condensed Financial Statements for a description of the Company’s plan
to redeem the 2022 Euronotes in the fourth quarter of 2020.
Stock Repurchase Program
For information regarding the Company’s stock repurchase program, refer to Part II—Item 2, “Unregistered Sales of Equity
Securities and Use of Proceeds”.
Dividends
Aggregate cash payments for dividends on Company common stock during the nine-month period ended October 2, 2020 were
$371 million and aggregate cash payments for dividends on the Company’s MCPS Shares during the nine-month period ended
October 2, 2020 were $74 million. The increase in dividend payments over the comparable period of 2019 primarily relates to
dividends paid on the MCPS Series A and MCPS Series B, which were issued March 1, 2019 and May 12, 2020, respectively,
as well as an increase in the quarterly dividend rate for common stock beginning with respect to the dividend paid in the second
quarter of 2019.
In the third quarter of 2020, the Company declared a regular quarterly dividend of $0.18 per share of Company common stock
payable on October 30, 2020 to holders of record as of September 28, 2020. In addition, the Company declared a quarterly cash
dividend of $11.875 per MCPS Series A that was paid on October 15, 2020 to holders of record as of September 30, 2020 and
quarterly cash dividend of $12.50 per MCPS Series B that was paid on October 15, 2020 to holders of record as of September
30, 2020.
Cash and Cash Requirements
As of October 2, 2020, the Company held approximately $5.7 billion of cash and cash equivalents that were held on deposit
with financial institutions or invested in highly liquid investment-grade debt instruments with a maturity of 90 days or less. The
Company expects interest income earned on cash in future periods to decline compared to prior periods, as the interest income
earned in prior periods was driven by the funds raised to finance the Cytiva Acquisition. Of the cash and cash equivalents,
approximately $2.2 billion was held within the United States and approximately $3.5 billion was held outside of the United
Table of Contents
51

-- 54 of 73 --

States. The Company will continue to have cash requirements to support general corporate purposes, which may include
working capital needs, capital expenditures and acquisitions, paying interest and servicing debt, paying taxes and any related
interest or penalties, funding its restructuring activities and pension plans as required, paying dividends to shareholders,
repurchasing shares of the Company’s common stock and supporting other business needs.
The Company generally intends to use available cash and internally generated funds to meet these cash requirements, but in the
event that additional liquidity is required, the Company may also borrow under its commercial paper programs (if available) or
the Credit Facilities, enter into new credit facilities and either borrow directly thereunder or use such credit facilities to backstop
additional borrowing capacity under its commercial paper programs (if available) and/or access the capital markets (if
available). The Company also may from time to time seek to access the capital markets to take advantage of favorable interest
rate environments or other market conditions. With respect to the commercial paper scheduled to mature during the remainder
of 2020, the Company expects to repay the principal amounts when due using available cash, proceeds from new issuances of
commercial paper (if available), drawing on its Credit Facilities and/or proceeds from other debt issuances.
While repatriation of some cash held outside the United States may be restricted by local laws, most of the Company’s foreign
cash could be repatriated to the United States. Following enactment of the Tax Cuts and Jobs Act and the associated Transition
Tax, in general, repatriation of cash to the United States can be completed with no incremental U.S. tax; however, repatriation
of cash could subject the Company to non-U.S. taxes on distributions. The cash that the Company’s non-U.S. subsidiaries hold
for indefinite reinvestment is generally used to finance foreign operations and investments, including acquisitions. The income
taxes, if any, applicable to such earnings including basis differences in our foreign subsidiaries are not readily determinable. As
of October 2, 2020, management believes that it has sufficient sources of liquidity to satisfy its cash needs, including its cash
needs in the United States.
During 2020, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are
forecasted to be approximately $85 million and $50 million, respectively. The ultimate amounts to be contributed depend upon,
among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of
the contribution, local practices, market conditions, interest rates and other factors. On March 27, 2020, the Coronavirus Aid,
Relief, and Economic Security (“CARES”) Act was signed into law and includes a provision that allows employers to defer
payment of contributions to U.S. defined benefit pension plans due in 2020 until January 1, 2021. The Company has not
elected to defer any 2020 contributions to its U.S. defined benefit pension plans pursuant to this provision.
CRITICAL ACCOUNTING ESTIMATES
There were no material changes to the Company’s critical accounting estimates described in the 2019 Annual Report that have a
material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Financial Instruments and Risk Management,” in the Company’s 2019 Annual Report.
There were no material changes during the quarter ended October 2, 2020 to this information reported in the Company’s 2019
Annual Report.
ITEM 4. CONTROLS AND PROCEDURES
The Company’s management, with the participation of the Company’s President and Chief Executive Officer, and Executive
Vice President and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and
procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the Company’s President
and Chief Executive Officer, and Executive Vice President and Chief Financial Officer, have concluded that, as of the end of
such period, the Company’s disclosure controls and procedures were effective.
There have been no changes in the Company’s internal control over financial reporting (as such term is defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the Company’s most recent completed fiscal quarter that
have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Table of Contents
52

-- 55 of 73 --

PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For additional information regarding legal proceedings, refer to the section titled “Legal Proceedings” in the MD&A section of
the Company’s 2019 Annual Report.
ITEM 1A. RISK FACTORS
Except to the extent set forth below, there were no material changes during the quarter ended October 2, 2020 to the risk factors
reported in the Company's 2019 Annual Report, First Quarter 2020 Form 10-Q, or Second Quarter 2020 Form 10-Q. The
COVID-19 pandemic has heightened, and in some cases manifested, certain of the risks we normally face in operating our
business, including those disclosed in the Company's 2019 Annual Report, First Quarter 2020 Form 10-Q and Second Quarter
2020 Form 10-Q and the risk factor disclosure in the Company's 2019 Annual Report, First Quarter 2020 Form 10-Q and
Second Quarter 2020 Form 10-Q is qualified by the risk factor disclosure set forth below and the other information relating to
COVID-19 that is described in this Quarterly Report on Form 10-Q. Additional information regarding risk factors can be found
in “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Information Related to
Forward-Looking Statements,” in Part I—Item 2 of this Form 10-Q, in Part I—Item 1A of the Company’s 2019 Annual Report
and in Part II, Item 1A of the First Quarter 2020 Form 10-Q and Second Quarter 2020 Form 10-Q.
The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, results of operations and
financial condition, the nature and extent of which are highly uncertain and unpredictable.
Our global operations expose us to risks associated with public health crises, including epidemics and pandemics such as
COVID-19. The global spread of COVID-19 has led to unprecedented restrictions on, and disruptions in, business and personal
activities, including as a result of preventive and precautionary measures that we, other businesses, our communities and
governments are taking to mitigate the spread. For example, many governments have issued “stay-at-home” orders which
restrict business and personal activities, and many employers are requiring employees to work from home. In addition to
existing travel and activity restrictions, jurisdictions may continue to close borders, impose prolonged quarantines and further
restrict travel and other activities. The pandemic has caused a global recession of potentially extended duration.
The direct impact of COVID-19 and the preventive and precautionary measures implemented as a result thereof have adversely
affected, and are expected to continue to adversely affect, certain elements of our Company (including to a different degree our
operations, commercial organizations, supply chains and distribution systems) and the future impact may be material, though
the impact on our different businesses and the different elements of our businesses varies (please see “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” for a discussion of how COVID-19 impacted our
results of operations and financial position in the first nine months of 2020). Without limiting the foregoing, we have
experienced and/or may in the future experience:
• adverse impacts on customer orders and purchases and unpredictable reductions in demand for many of our products;
• constraints on the movement of our products through the supply chain;
• adverse impacts on our collections of accounts receivable, including delays in collections and increases in
uncollectible receivables;
• supply chain capacity constraints and price increases, including with respect to freight services;
• adverse impacts on our workforce and/or key employees;
• unpredictable increases in demand for certain products; and
• increased cybersecurity threat activity.
In an effort to optimize availability of needed medical and other supplies and products in connection with the COVID-19
pandemic, we may elect to or governments may require us or our customers to allocate manufacturing capacity (for example
pursuant to the U.S. Defense Production Act (“DPA”)) in a way that adversely affects our financial condition and results of
operations, results in differential treatment of customers and/or adversely affects our reputation and customer relationships. For
example, certain of our customers are or have been subject to DPA requirements relating to the production of COVID-19
related products and have required certain of our businesses to also comply with these requirements under our supply
agreements. Further, the Biomedical Advanced Research and Development Authority (“BARDA”) of the U.S. government has
agreed to finance an expansion of production capacity at one of our businesses for COVID-19 related products, and in
Table of Contents
53

-- 56 of 73 --

connection therewith the business has committed certain of such incremental production capacity to the U.S. government
pursuant to the DPA. In addition, unpredictable increases in demand for certain of our products can exceed our capacity to
meet such demand on a timely basis or at all, which can adversely affect our financial condition, results of operations and
customer relationships and result in negative publicity. The accelerated development and production of products and services
in an effort to address medical and other requirements as a result of the pandemic also increases the risk of regulatory
enforcement actions, product defects or claims thereof. In addition, if one or more vaccines for COVID-19 are successfully
developed, such vaccines may not use Danaher’s vaccine development/production solutions; and if the number of COVID-19
vaccines under development declines (for example because one or a limited number of vaccines emerges as the preferred
solution) the demand for Danaher’s vaccine development/production solutions may decline. Danaher’s COVID-19 testing
solutions may also not ultimately be the preferred testing solutions for COVID-19. Any of these developments may adversely
affect our business, financial condition and results of operations.
Although we successfully issued Euro-denominated senior notes in underwritten offerings March and April 2020, issued U.S.
dollar-denominated senior notes in October 2020 and issued common stock and preferred stock in May 2020, COVID-19 has
led to disruption and volatility in the global capital markets, which has increased the cost of, and adversely impacted access to,
capital (including in the commercial paper markets) and increased economic uncertainty. There are no assurances that the
commercial paper markets or the capital markets will be available to us in the future or that the lenders participating in our
revolving credit facilities will be able to provide financing in accordance with their contractual obligations.
While the pandemic continues we expect to experience continued adverse impacts on our business, financial condition and
results of operations, which adverse impacts are unpredictable and may be material. Even to the extent COVID-19 conditions
begin to improve, the duration and sustainability of any such improvements will be uncertain and continuing adverse impacts
and/or the degree of improvement may vary dramatically by geography and line of business. The actions Danaher’s businesses
take in response to any improvements in conditions may vary widely by geography and line of business and will likely be made
with incomplete information; pose the risk that such actions may prove to be premature, incorrect or insufficient; and could
have a material, adverse impact on Danaher. In addition, any restructuring activities we undertake in light of the COVID-19
impact may adversely affect our business, financial condition and results of operations.
The Cytiva Acquisition could negatively impact our business, results of operations and financial condition.
The Cytiva Acquisition is Danaher’s largest acquisition to date based on purchase price, expanded Danaher’s business into new
fields and involves a number of financial, accounting, managerial, operational, legal, compliance and other risks and challenges,
including those listed below. Any of these risks or challenges could adversely affect our business, financial statements and
stock price.
• The Cytiva business could under-perform relative to our expectations and the price that we paid or not perform in
accordance with our anticipated timetable, or we could fail to operate such business profitably.
• The Cytiva Acquisition could cause our financial results to differ from our own or the investment community’s
expectations in any given period, or over the long-term.
• Earnings charges related to the Cytiva Acquisition could adversely impact operating results in any given period, and
the impact may be substantially different from period-to-period.
• The Cytiva Acquisition has created incremental demands on our management, operational resources and financial and
internal control systems, and we may be unable to effectively address these demands.
• The Cytiva Acquisition requires management’s attention and other resources, which could have a negative impact on
our ability to manage existing operations or pursue other strategic transactions.
• We could experience difficulty or greater-than-anticipated costs in integrating the personnel, operations and financial
and other controls and systems of Cytiva and could experience difficulty attracting and retaining key employees and
customers.
• We may be unable to achieve anticipated cost savings or other synergies on the timetable we expect or at all.
• We may have assumed unknown liabilities, known contingent liabilities that become realized, known liabilities that
prove greater than anticipated, internal control deficiencies or exposure to regulatory sanctions resulting from Cytiva’s
activities and the realization of any of these liabilities or deficiencies may increase our expenses, adversely affect our
financial position or cause us to fail to meet our public financial reporting obligations.
Table of Contents
54

-- 57 of 73 --

• As a result of the Cytiva Acquisition, we are recording significant goodwill and other assets on our balance sheet and if
we are not able to realize the value of these assets, we may be required to incur impairment charges.
Our outstanding debt has increased significantly as a result of the Cytiva Acquisition, and we may incur additional debt in
the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively
impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect
our liquidity and financial statements.
As of October 2, 2020, we had approximately $21.8 billion in outstanding indebtedness. Our debt level and related debt service
obligations (as well as the dividend obligations pursuant to the MCPS Series A and Series B) can have negative consequences,
including (1) requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt
(or dividends on our convertible preferred stock), which reduces the funds we have available for other purposes such as
acquisitions and other investments; (2) reducing our flexibility in planning for or reacting to changes in our business and market
conditions; and (3) exposing us to interest rate risk since a portion of our debt obligations are at variable rates.
Upon closing of the Cytiva Acquisition, our long-term unsecured debt credit rating was downgraded to BBB + by Standard &
Poor’s and Baa1 by Moody’s, each two notches below our long-term unsecured debt credit rating prior to the closing of the
Cytiva Acquisition. This reduction in our credit ratings may limit our ability to borrow at interest rates consistent with the
interest rates that have been available to us prior to the Cytiva Acquisition. If our credit ratings are further downgraded or put
on watch for a further potential downgrade, we may not be able to sell additional debt securities or borrow money in the
amounts, at the times or interest rates or upon the more favorable terms and conditions that might be available if our current
credit ratings were maintained.
Our credit facilities and long-term debt obligations also impose certain restrictions on us, including certain restrictions on our
ability to incur liens on our assets, and a requirement under our credit facilities to maintain a consolidated leverage ratio (the
ratio of consolidated indebtedness to consolidated indebtedness plus shareholders’ equity) of 0.65 to 1.0 or less. If we breach
any of these restrictions and cannot obtain a waiver from the lenders on favorable terms, subject to applicable cure periods, the
outstanding indebtedness (and any other indebtedness with cross-default provisions) could be declared immediately due and
payable, which would adversely affect our liquidity and financial statements. If we add new debt in the future, the risks
described above would increase.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the nine-month
period ended October 2, 2020. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the
“Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to
time on the open market or in privately negotiated transactions. There is no expiration date for the Repurchase Program, and
the timing and amount of any shares repurchased under the program will be determined by the Company’s management based
on its evaluation of market conditions and other factors. The Repurchase Program may be suspended or discontinued at any
time. Any repurchased shares will be available for use in connection with the Company’s equity compensation plans (or any
successor plans) and for other corporate purposes. As of October 2, 2020, 20 million shares remained available for repurchase
pursuant to the Repurchase Program. The Company expects to fund any future stock repurchases using the Company’s
available cash balances or proceeds from the issuance of debt.
During the third quarter of 2020, holders of certain of the Company’s Liquid Yield Option Notes due 2021 (“LYONS”)
converted such LYONS into an aggregate of 4 thousand shares of Danaher common stock, par value $0.01 per share. In each
case, the shares of common stock were issued solely to existing security holders upon conversion of the LYONs pursuant to the
exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933, as amended.
Table of Contents
55

-- 58 of 73 --

ITEM 6. EXHIBITS
(a) Exhibits:
3.1 Restated Certificate of Incorporation of Danaher Corporation (incorporated by reference from Exhibit 3.1 to
Danaher Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2012)
3.2
Certificate of Designations of the 4.75% Mandatory Convertible Preferred Stock, Series A, filed with the Secretary
of State of the State of Delaware on February 28, 2019 (incorporated by reference from Exhibit 3.1 to Danaher
Corporation’s Current Report on Form 8-K filed March 1, 2019)
3.3
Certificate of Designations of the 5.00% Mandatory Convertible Preferred Stock, Series B, filed with the Secretary
of State of the State of Delaware on May 11, 2020 (incorporated by reference from Exhibit 3.1 to Danaher
Corporation’s Current Report on Form 8-K filed May 12, 2020)
3.4 Amended and Restated By-laws of Danaher Corporation (incorporated by reference from Exhibit 3.2 to Danaher
Corporation’s Current Report on Form 8-K filed December 6, 2016)
10.1
Aircraft Time Sharing Agreement by and between Danaher Corporation and Rainer M. Blair, dated as of August 3,
2020 *
31.1 Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
32.2 Certification of Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Indicates management contract or compensatory plan, contract or arrangement.
Table of Contents
56

-- 59 of 73 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
DANAHER CORPORATION
Date: October 21, 2020 By: /s/ Matthew R. McGrew
Matthew R. McGrew
Executive Vice President and Chief Financial Officer
Date: October 21, 2020 By: /s/ Robert S. Lutz
Robert S. Lutz
Senior Vice President and Chief Accounting Officer
Table of Contents
57

-- 60 of 73 --

AIRCRAFT TIME SHARING AGREEMENT
THIS AIRCRAFT TIME SHARING AGREEMENT (this “Agreement”) is entered into
as of August 3, 2020 by and between Danaher Corporation (“Owner”), a Delaware corporation,
with principal offices at 2200 Pennsylvania Avenue, NW, Suite 800W, Washington, DC 20037
and Rainer M. Blair (“Lessee”).
BACKGROUND:
A. Owner owns or leases and operates certain civil aircraft identified on Exhibit A to this
Agreement (collectively, the “Aircraft” and, individually, an “Aircraft”).
B. Owner employs fully qualified flight crews to operate the Aircraft; and
C. From time to time, Lessee may desire to lease the Aircraft with a flight crew from
Owner for Lessee’s personal travel at Lessee’s discretion on a non-exclusive time sharing basis
as defined in Section 91.501(c)(1) of the Federal Aviation Regulations (“FAR”).
NOW, THEREFORE, Owner and Lessee agree as follows:
1. This Agreement shall govern personal use of the Aircraft by Lessee or by family
members or guests of Lessee as and to the extent set forth in such policy or policies as the Board
of Directors of Owner, or the Compensation Committee thereof, shall adopt from time to time.
Subject to the terms and conditions of this Agreement, Owner agrees to lease, from time to time
on a non-exclusive and non-continuous basis, the Aircraft to Lessee for Lessee’s personal travel
at Lessee’s discretion pursuant to the provisions of FAR Sections 91.501(b)(6), 91.501(c)(1) and
91.501(d) and to provide a fully qualified flight crew for all operations for flights scheduled in
accordance with the terms of this Agreement during the period commencing on the date of this
Agreement and terminating on the earlier of (a) the termination of this Agreement by consent of
Owner and Lessee, (b) the date of Lessee’s termination of employment with Owner and (c) the
date of Lessee’s death. Owner shall have the right to add or substitute aircraft of similar type,
quality, and equipment, and to remove aircraft from the fleet, from time to time during the term
of this Agreement. Owner shall send Lessee a revised Exhibit A upon each such change in the
Aircraft.
2. For each flight conducted under this Agreement, Lessee shall pay Owner no more
than the actual, incremental cost to the Owner of such flight but only to the extent authorized by
FAR Section 91.501(d) as in effect from time to time. As of the effective date of this Agreement,
such payment from Lessee to Owner for any specific flight shall not exceed:
(a) fuel, oil, lubricants and other additives;
(b) travel expenses of the crew, including food, lodging and ground
transportation;
(c) hangar and tie down costs away from the Aircraft’s base of operation;
(d) insurance obtained for the specific flight;
Exhibit 10.1

-- 61 of 73 --

(e) landing fees, airport taxes and similar assessments;
(f) customs, foreign permit and similar fees directly related to the flight;
(g) in-flight food and beverages;
(h) passenger ground transportation;
(i) flight planning and weather contract services;
(j) an additional charge equal to one hundred percent (100%) of the expenses
listed in clause (a) above.
3. Owner will pay all expenses related to the operation of each Aircraft when incurred
and will provide quarterly invoices to Lessee for the expenses enumerated in Section 2 above.
The Owner and Lessee acknowledge that, with the exception of the expenses for in-flight food
and beverages and passenger ground transportation, the payment of these expenses are subject to
the federal excise tax imposed under Section 4261 of the Internal Revenue Code. Lessee shall
reimburse Owner for the expenses authorized by FAR Section 91.501(d) plus applicable federal
excise taxes within thirty (30) calendar days after receipt of the related invoice. Owner agrees to
collect and remit to the Internal Revenue Service for the benefit of Lessee all such federal excise
taxes.
4. In the event that Lessee desires to use the Aircraft pursuant to this Agreement,
Lessee will so notify Owner and will provide Owner with requests for flight time and proposed
flight schedules as far as possible in advance of any given flight. Requests for flight time shall be
in a form, whether oral or written, mutually convenient to and agreed upon by Owner and
Lessee. In addition to proposed schedules and flight times, Lessee shall provide at least the
following information for each proposed flight at some time prior to scheduled departure as
required by Owner or Owner's flight crew:
(a) departure point;
(b) destinations;
(c) date and time of flight;
(d) the identity of each anticipated passenger;
(e) the nature and extent of luggage or cargo to be carried;
(f) the date and time of a return flight, if any; and
(g) any other information concerning the proposed flight that may be pertinent
or required by Owner or Owner's flight crew.
5. Owner shall have sole and exclusive authority over the scheduling of the Aircraft,
including which Aircraft is used for any particular flight. Lessee’s use of the Aircraft shall be on
a non-exclusive and non-continuous basis and as needed and as available. Owner shall have the

-- 62 of 73 --

right to cancel Lessee’s proposed use of the Aircraft by telephonic or other notice to Lessee at
any time prior to the departure of the Aircraft. Owner retains the right, during the Term, (a) to
use and operate the Aircraft under FAR Part 91 and (b) to the extent permitted by the FARs, to
lease and/or furnish (under separate time sharing or interchange agreements) the Aircraft to one
or more third parties who may also use and/or operate the Aircraft under FAR Part 91.
6. Owner shall be solely responsible for securing maintenance, preventive
maintenance, and required or otherwise necessary inspections on the Aircraft and shall take such
requirements into account in scheduling flights of the various Aircraft. No period of
maintenance, preventive maintenance, or inspection shall be delayed or postponed for the
purpose of scheduling the Aircraft, unless such maintenance or inspection can be safely
conducted at a later time in compliance with all applicable laws and regulations, and within the
sound discretion of the pilot-in-command. The pilot-in-command shall have final and complete
authority to cancel any flight for any reason or condition that in his or her judgment would
compromise the safety of the flight.
7. Owner shall be responsible for the physical and technical operation of the Aircraft
and the safe performance of all flights and shall retain full authority and control, including
exclusive operational control, and possession of the Aircraft at all times during the term of this
Agreement. Without limiting the generality of the foregoing, Owner shall exercise exclusive
authority over initiating, conducting or terminating any flight undertaken under this Agreement.
Owner shall employ, pay for, and provide to Lessee a qualified flight crew for each flight
undertaken under this Agreement. In accordance with applicable FAR, the qualified flight crew
provided by Owner will exercise all required and/or appropriate duties and responsibilities with
respect to the safety of each flight conducted under this Agreement. The pilot-in-command shall
have absolute discretion in all matters concerning the preparation of the Aircraft for flight and
the flight itself, the load carried and its distribution, the decision whether or not a flight shall be
undertaken, the route to be flown, the place where landings shall be made and all other matters
relating to operation of the Aircraft. Lessee specifically agrees that the flight crew shall have
final and complete authority to delay or cancel any flight for any reason or condition which, in
the sole judgment of the pilot-in-command, could compromise the safety of the flight and to take
any other action which, in the sole judgment of the pilot in command, is necessitated by
considerations of safety. Without limiting the generality of Section 8, no such action of the pilot-
in-command shall create or support any liability for loss, injury, damage, or delay to Lessee or
any other person.
8. The Owner and Lessee agree that Owner shall not be liable to Lessee or any other
person for loss, injury, or damage occasioned by the delay or failure to furnish the Aircraft and
crew pursuant to this Agreement for any reason.
9. The risk of loss during the period when any Aircraft is operated on behalf of Lessee
under this Agreement shall remain with Owner, and Owner will retain all rights and benefits with
respect to the proceeds payable under policies of hull insurance maintained by Owner that may
be payable as a result of any incident or occurrence while an Aircraft is being operated on behalf
of Lessee under this Agreement. Lessee shall be named as an additional insured on aviation
liability insurance policies maintained by Owner on the Aircraft with respect to flights conducted

-- 63 of 73 --

pursuant to this Agreement. The liability insurance policies on which Lessee is named an
additional insured shall provide that as to Lessee coverage shall not be invalidated or adversely
affected by any action or inaction, omission or misrepresentation by Owner or any other person
(other than Lessee). Any insurance policies maintained by Owner on any Aircraft used by Lessee
under this Agreement shall include a waiver of any rights of subrogation of the insurers against
Lessee and shall be primary without any right of contribution from any other insurance available
to any other insureds or additional insureds.
10. A copy of this Agreement shall be carried in the Aircraft and available for review
upon the request of the FAA on all flights conducted pursuant to this Agreement.
11. Lessee represents, warrants and covenants to Owner that:
(a) he will use each Aircraft for and on his own account only and will not use
any Aircraft for the purposes of providing transportation of passengers or
cargo in air commerce for compensation or hire;
(b) he shall refrain from incurring any mechanics or other lien in connection
with inspection, preventative maintenance, maintenance or storage of the
Aircraft, whether permissible or impermissible under this Agreement, and he
shall not attempt to convey, mortgage, assign, lease or any way alienate the
Aircraft or create any kind of lien or security interest involving the Aircraft
or do anything or take any action that might mature into such a lien;
(c) during the term of this Agreement, he will abide by and conform to all such
laws, governmental, and airport orders, rules, and regulations as shall from
time to time be in effect relating in any way to the operation and use of the
Aircraft by a time-sharing lessee.
12. For purposes of this Agreement, the permanent base of operation of the Aircraft
shall be Washington Dulles International Airport, 23411 Autopilot Drive, Dulles, Virginia,
unless changed by Owner, in which event Owner shall notify Lessee of the new permanent base
of operation of the Aircraft.
13. Owner and Lessee agree that the insurance specified in Section 9 shall provide the
sole recourse to Lessee, his family members or guests on the Aircraft, their personal
representatives and any person claiming by, through, or under them (collectively, the “Lessee
Parties”) for all claims, losses, liabilities, obligations, demands, suits, judgments or causes of
action, penalties, fines, costs and expenses of any nature whatsoever, including attorneys’ fees
and expenses (each, a “Claim” and collectively, the “Claims”) for or on account of, or arising out
of, or in any way connected with Owner’s breach of this Agreement or possession, maintenance,
storage, use or operation of the Aircraft, including injury to or death of any persons, which may
result from, arise out of, or is in any way connected with the possession, maintenance, storage,
use or operation of the Aircraft during the term of this Agreement. WITHOUT LIMITING THE
FOREGOING, IN NO EVENT SHALL OWNER OR ANY OF ITS AFFILIATES OR THEIR
RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, MANAGERS, EMPLOYEES OR
AGENTS BE LIABLE TO ANY OF THE LESSEE PARTIES OR ANY OTHER THIRD
PARTIES, AS THE CASE MAY BE, FOR (i) ANY CLAIMS IN EXCESS OF THE AMOUNT

-- 64 of 73 --

PAID TO ANY OF THE LESSEE PARTIES OR ANY OTHER THIRD PARTIES, AS
APPLICABLE, BY OWNER’S INSURANCE CARRIER, OR (ii) ANY INDIRECT,
SPECIAL, CONSEQUENTIAL AND/OR PUNITIVE DAMAGES OF ANY KIND OR
NATURE UNDER ANY CIRCUMSTANCES OR FOR ANY REASON INCLUDING ANY
DELAY OR FAILURE TO FURNISH ANY OF THE AIRCRAFT OR CAUSED OR
OCCASIONED BY THE PERFORMANCE OR NON-PERFORMANCE OF ANY SERVICES
COVERED BY THIS AGREEMENT.
14. Neither this Agreement nor any party’s interest in this Agreement shall be
assignable to any other person or entity. This Agreement shall be binding upon, and shall inure to
the benefit of, the parties hereto and their respective successors and personal representatives.
Nothing in this Agreement, express or implied, is intended to confer on any person or entity,
other than the parties and their respective successors and personal representatives, any rights,
remedies, benefits, obligations or liabilities hereunder, except as specifically provided herein or
otherwise specifically agreed to in writing by the parties.
15. This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware (excluding the conflicts of law rules thereof).
16. This Agreement constitutes the entire understanding between Owner and Lessee
with respect to its subject matter, and there are no representations, warranties, conditions,
covenants, or agreements other than as set forth expressly herein. Any amendments, waivers or
modifications of or to this Agreement shall be in writing and signed by authorized
representatives of both parties. This Agreement may be executed in counterparts, which shall,
singly or in the aggregate, constitute a fully executed and binding agreement.
17. Any notice, request, or other communication to any party by the other party under
this Agreement shall be conveyed in writing and shall be deemed given on the earlier of the date
(i) notice is personally delivered with receipt acknowledged, (ii) a facsimile notice is transmitted,
or (iii) three (3) calendar days after notice is mailed by certified mail, return receipt requested,
postage paid, and addressed to the party at the address set forth below. The address of a party to
which notices or copies of notice are to be given may be changed from time to time by such party
by written notice to the other party.
If to Owner:
Danaher Corporation
2200 Pennsylvania Avenue, NW
Suite 800W
Washington, DC 20037
Attention: General Counsel
Fax: 202-828-0860

-- 65 of 73 --

If to Lessee:
Rainer M. Blair
Danaher Corporation
2200 Pennsylvania Avenue, NW
Suite 800W
Washington, DC 20037
Fax: 202-828-0860
18. If any one or more of the provisions of the Agreement shall be held invalid, illegal,
or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the
invalid, illegal, or unenforceable provision shall be replaced by a mutually acceptable provision,
which, being valid, legal, and enforceable, comes closest to the intention of the parties
underlying the invalid, illegal, or unenforceable provision. To the extent permitted by applicable
law, the parties hereby waive any provision of law, which renders any provision of this
Agreement prohibited or unenforceable in any respect. The failure or delay on the part of any
party hereto to insist upon or enforce strict performance of any provision of this Agreement by
any other party hereto, or to exercise any right, power or remedy under this Agreement, shall not
be deemed or construed as a waiver thereof. A waiver by any party hereto of any provision of
this Agreement or of any breach thereof shall not be deemed or construed as a general waiver
thereof or of any other provision or rights thereunder.
19. THE AIRCRAFT SHALL BE LEASED TO LESSEE HEREUNDER IN AN “AS
IS, WHERE IS” CONDITION. NEITHER OWNER (NOR ITS AFFILIATES) MAKES, HAS
MADE OR SHALL BE DEEMED TO MAKE OR HAVE MADE, AND OWNER (FOR
ITSELF AND ITS AFFILIATES) HEREBY DISCLAIMS, ANY WARRANTY OR
REPRESENTATION, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, WITH
RESPECT TO ANY AIRCRAFT TO BE USED HEREUNDER OR ANY ENGINE OR
COMPONENT THEREOF INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS
TO DESIGN, COMPLIANCE WITH SPECIFICATIONS, QUALITY OF MATERIALS OR
WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANY PURPOSE, USE OR
OPERATION, AIRWORTHINESS, SAFETY, PATENT, TRADEMARK OR COPYRIGHT
INFRINGEMENT OR TITLE. .
20. The limitations of liability, disclaimers and exculpations set forth in this Agreement
shall survive the termination of this Agreement, whether by its terms, by operation of law or
otherwise.
21. With respect to the Truth in leasing requirements of FAR Section 91.23:

-- 66 of 73 --

(a) Owner will provide a copy of this Agreement to the Federal Aviation
Administration, Aircraft Registration Branch, Technical Section, in
Oklahoma City, Oklahoma within twenty-four hours of its execution. In
addition, Owner will notify the FAA flight standards district office nearest
the airport where the first flight under this Agreement will originate and
provide it with a copy of this Agreement at least forty-eight (48) hours
before takeoff of such flight, informing the FAA of (i) the location of the
airport of departure; (ii) the departure time; and (iii) the registration number
of the aircraft involved;
(b) Truth in leasing statement under FAR Section 91.23:
(i) OWNER HEREBY CERTIFIES THAT EACH AIRCRAFT HAS
BEEN INSPECTED AND MAINTAINED WITHIN THE TWELVE
(12) MONTH PERIOD PRECEDING THE EXECUTION OF THIS
AGREEMENT, EXCEPT TO THE EXTENT THE AIRCRAFT IS
LESS THAN TWELVE (12) MONTHS OLD, IN ACCORDANCE
WITH THE PROVISIONS OF FAR PART 91. EACH OF OWNER
AND LESSEE CERTIFIES THAT THE AIRCRAFT WILL BE
MAINTAINED AND INSPECTED IN COMPLIANCE WITH THE
APPLICABLE MAINTENANCE AND INSPECTION
REQUIREMENTS OF FAR PART 91 FOR ALL OPERATIONS TO
BE CONDUCTED DURING THE TERM OF THIS AGREEMENT.
(ii) OWNER, WHOSE NAME AND ADDRESS ARE SET FORTH
ABOVE, SHALL BE SOLELY RESPONSIBLE FOR
OPERATIONAL CONTROL OF THE AIRCRAFT DURING THE
TERM OF THIS AGREEMENT.
(iii) EACH OF OWNER AND LESSEE CERTIFIES THAT IT
UNDERSTANDS ITS RESPONSIBILITIES FOR COMPLIANCE
WITH APPLICABLE FEDERAL AVIATION REGULATIONS.
(iv) AN EXPLANATION OF FACTORS BEARING ON
OPERATIONAL CONTROL AND PERTINENT FARS CAN BE
OBTAINED FROM THE NEAREST FAA FLIGHT STANDARDS
DISTRICT OFFICE, GENERAL AVIATION DISTRICT OFFICE,
OR AIR CARRIER DISTRICT OFFICE.
[SIGNATURES ON FOLLOWING PAGE]

-- 67 of 73 --

IN WITNESS WHEREOF, Owner and Lessee have caused the signatures of their
authorized representatives to be affixed below on the day and year first above written.
DANAHER CORPORATION
By: /s/ Steven Rales
Name: Steven Rales
Title: Chairman
/s/ Rainer M. Blair
Name: Rainer M. Blair

-- 68 of 73 --

Exhibit A
United States Registration
Number
Aircraft Type Manufacturer’s
Serial Number
N886DC Dassault Falcon 900B
N807DC Bombardier Global Express XRS

-- 69 of 73 --

Exhibit 31.1
Certification
I, Rainer M. Blair, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Danaher Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;
b. designed such internal control over financial reporting, or caused such internal control over financial reporting to
be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;
c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or
persons performing the equivalent functions):
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and
report financial information; and
b. any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant's internal control over financial reporting.
Date: October 21, 2020 By: /s/ Rainer M. Blair
Rainer M. Blair
President and Chief Executive Officer

-- 70 of 73 --

Exhibit 31.2
Certification
I, Matthew R. McGrew, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Danaher Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;
b. designed such internal control over financial reporting, or caused such internal control over financial reporting to
be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;
c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or
persons performing the equivalent functions):
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and
report financial information; and
b. any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant's internal control over financial reporting.
Date: October 21, 2020 By: /s/ Matthew R. McGrew
Matthew R. McGrew
Executive Vice President and Chief Financial Officer

-- 71 of 73 --

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Rainer M. Blair, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that to my knowledge, Danaher Corporation’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 2,
2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that
information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and
results of operations of Danaher Corporation.
Date: October 21, 2020 By: /s/ Rainer M. Blair
Rainer M. Blair
President and Chief Executive Officer
This certification accompanies the Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that
section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act or the
Exchange Act, except to the extent that Danaher Corporation specifically incorporates it by reference.

-- 72 of 73 --

Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Matthew R. McGrew, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to my knowledge, Danaher Corporation’s Quarterly Report on Form 10-Q for the fiscal quarter ended
October 2, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that
information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and
results of operations of Danaher Corporation.
Date: October 21, 2020 By: /s/ Matthew R. McGrew
Matthew R. McGrew
Executive Vice President and Chief Financial Officer
This certification accompanies the Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that
section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act or the
Exchange Act, except to the extent that Danaher Corporation specifically incorporates it by reference.

-- 73 of 73 --